<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72500</article-id><article-id pub-id-type="doi">10.7554/eLife.72500</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-251951"><name><surname>Sonnweber</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5080-386X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-247291"><name><surname>Tymoszuk</surname><given-names>Piotr</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0398-6034</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-251952"><name><surname>Sahanic</surname><given-names>Sabina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-251953"><name><surname>Boehm</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-251954"><name><surname>Pizzini</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-251955"><name><surname>Luger</surname><given-names>Anna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0445-8372</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-251956"><name><surname>Schwabl</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252555"><name><surname>Nairz</surname><given-names>Manfred</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-265910"><name><surname>Grubwieser</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252045"><name><surname>Kurz</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252046"><name><surname>Koppelstätter</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252047"><name><surname>Aichner</surname><given-names>Magdalena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252048"><name><surname>Puchner</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252049"><name><surname>Egger</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252556"><name><surname>Hoermann</surname><given-names>Gregor</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-252051"><name><surname>Wöll</surname><given-names>Ewald</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252052"><name><surname>Weiss</surname><given-names>Günter</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-252053"><name><surname>Widmann</surname><given-names>Gerlig</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-252054"><name><surname>Tancevski</surname><given-names>Ivan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5116-8960</contrib-id><email>Ivan.Tancevski@i-med.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-252055"><name><surname>Löffler-Ragg</surname><given-names>Judith</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0873-7501</contrib-id><email>Judith.Loeffler@i-med.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pt86f80</institution-id><institution>Department of Internal Medicine II, Medical University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pt86f80</institution-id><institution>Department of Radiology, Medical University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution>The Karl Landsteiner Institute</institution><addr-line><named-content content-type="city">Muenster</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pt86f80</institution-id><institution>Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00smdp487</institution-id><institution>Munich Leukemia Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution>Department of Internal Medicine, St. Vinzenz Hospital</institution><addr-line><named-content content-type="city">Zams</named-content></addr-line><country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Data Analytics As a Service Tirol, Innsbruck, Austria</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e72500</elocation-id><history><date date-type="received" iso-8601-date="2021-07-26"><day>26</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-19"><day>19</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-06-25"><day>25</day><month>06</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.06.22.21259316"/></event></pub-history><permissions><copyright-statement>© 2022, Sonnweber et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Sonnweber et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72500-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72500-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>The optimal procedures to prevent, identify, monitor, and treat long-term pulmonary sequelae of COVID-19 are elusive. Here, we characterized the kinetics of respiratory and symptom recovery following COVID-19.</p></sec><sec id="abs2"><title>Methods:</title><p>We conducted a longitudinal, multicenter observational study in ambulatory and hospitalized COVID-19 patients recruited in early 2020 (n = 145). Pulmonary computed tomography (CT) and lung function (LF) readouts, symptom prevalence, and clinical and laboratory parameters were collected during acute COVID-19 and at 60, 100, and 180 days follow-up visits. Recovery kinetics and risk factors were investigated by logistic regression. Classification of clinical features and participants was accomplished by unsupervised and semi-supervised multiparameter clustering and machine learning.</p></sec><sec id="abs3"><title>Results:</title><p>At the 6-month follow-up, 49% of participants reported persistent symptoms. The frequency of structural lung CT abnormalities ranged from 18% in the mild outpatient cases to 76% in the intensive care unit (ICU) convalescents. Prevalence of impaired LF ranged from 14% in the mild outpatient cases to 50% in the ICU survivors. Incomplete radiological lung recovery was associated with increased anti-S1/S2 antibody titer, IL-6, and CRP levels at the early follow-up. We demonstrated that the risk of perturbed pulmonary recovery could be robustly estimated at early follow-up by clustering and machine learning classifiers employing solely non-CT and non-LF parameters.</p></sec><sec id="abs4"><title>Conclusions:</title><p>The severity of acute COVID-19 and protracted systemic inflammation is strongly linked to persistent structural and functional lung abnormality. Automated screening of multiparameter health record data may assist in the prediction of incomplete pulmonary recovery and optimize COVID-19 follow-up management.</p></sec><sec id="abs5"><title>Funding:</title><p>The State of Tyrol (GZ 71934), Boehringer Ingelheim/Investigator initiated study (IIS 1199-0424).</p></sec><sec id="abs6"><title>Clinical trial number:</title><p>ClinicalTrials.gov: NCT04416100</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>long COVID</kwd><kwd>post-COVID-19 syndrome</kwd><kwd>pulmonary recovery</kwd><kwd>computed tomography</kwd><kwd>machine learning</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Land Tirol</institution></institution-wrap></funding-source><award-id>GZ 71934</award-id><principal-award-recipient><name><surname>Löffler-Ragg</surname><given-names>Judith</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001003</institution-id><institution>Boehringer Ingelheim</institution></institution-wrap></funding-source><award-id>IIS 1199-0424</award-id><principal-award-recipient><name><surname>Tancevski</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Protracted systemic and microvascular inflammation, as well as high anti-SARS-CoV-2 antibody levels, is associated with a high risk of persistent structural and functional lung deficits 6 months after COVID-19.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The ongoing COVID-19 pandemic challenges health-care systems. As of December 2021, the John Hopkins dashboard (<xref ref-type="bibr" rid="bib12">Dong et al., 2020</xref>)⁠ reports 276 million cases and 5.4 million COVID-19-related deaths worldwide (<xref ref-type="bibr" rid="bib25">Johns Hopkins Coronavirus Resource Center, 2021</xref>)⁠. Although the vast majority of COVID-19 patients display mild disease, approximately 10–15% of cases progress to a severe condition and approximately 5% suffer from critical illness (<xref ref-type="bibr" rid="bib36">Perez-Saez, 2021</xref>; <xref ref-type="bibr" rid="bib21">Huang et al., 2020</xref>). Similar to severe acute respiratory syndrome (SARS) (<xref ref-type="bibr" rid="bib24">Hui et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Ng et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Ngai et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Lam et al., 2009</xref>)⁠, a significant portion of COVID-19 patients report lingering or recurring clinical impairment and cardiopulmonary recovery may take several months to years (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Caruso et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib15">Faverio et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Hellemons et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Zhou et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Venkatesan, 2021</xref>)⁠. This observation has led to the introduction of the term ‘long COVID,’ defined by the persistence of COVID-19 symptoms for more than 4 weeks, and the ‘post-acute sequelae of COVID-19’ (PASC) referring to symptom persistence for more than 12 weeks (<xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Shah et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Sudre et al., 2021b</xref>)⁠. Evidence-based strategies for prediction, monitoring, and treatment of PASC are urgently needed (<xref ref-type="bibr" rid="bib39">Raghu and Wilson, 2020</xref>)⁠.</p><p>We herein prospectively analyzed the prevalence of nonresolving structural and functional lung abnormalities and persistent COVID-19-related symptoms 6 months after diagnosis. Using univariate risk modeling as well as multiparameter clustering and machine learning (ML), we investigated sets of risk factors and tested the operability of ML classifiers at predicting protracted lung and symptom recovery. The classification and prediction procedures were implemented in an open-source risk assessment tool (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>).</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study design</title><p>The CovILD (‘Development of interstitial lung disease in COVID-19’) multicenter, longitudinal observational study (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>) was initiated in April 2020. Adult residents of Tyrol, Austria, with symptomatic, PCR-confirmed SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib54">WHO, 2021</xref>)⁠ were enrolled by the Department of Internal Medicine II at the Medical University of Innsbruck (primary follow-up center), St. Vinzenz Hospital in Zams, and the acute rehabilitation facility in Münster (<xref ref-type="table" rid="table1">Table 1</xref>). The participants were diagnosed with COVID-19 between 3 March and 29 June 2020. In course of the study, including the 2020 SARS-CoV-2 outbreak and follow-up visits, the regional health system was able to guarantee an unrestricted, optimal standard of diagnostics and care for all participants. Corticosteroids were not standard of care during the recruitment period of the study, thus were not administered as a therapy of acute COVID-19. Some participants with nonresolving pneumonia received systemic steroids beginning from week 4 post diagnosis at the discretion of the physician (<xref ref-type="table" rid="table2">Table 2</xref>). The analysis endpoints were the presence of any, mild (severity score ≤ 5), and moderate-to-severe (severity score &gt; 5) lung computed tomography (CT) abnormalities, impaired lung function (LF), and persistent COVID-19 symptoms at the 180-day follow-up visit (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of the study population.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" valign="bottom">Characteristics (% cohort)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Total participants – no.</td><td align="char" char="." valign="bottom">145</td></tr><tr><td align="left" valign="bottom">Mean age, years</td><td align="left" valign="bottom">57.3 (SD = 14.3)</td></tr><tr><td align="left" valign="bottom">Female sex</td><td align="left" valign="bottom">42.4% (n = 63)</td></tr><tr><td align="left" valign="bottom">Obesity (body mass index &gt;30 kg/m<sup>2</sup>)</td><td align="left" valign="bottom">19.3% (n = 28)</td></tr><tr><td align="left" valign="bottom">Ex-smoker</td><td align="left" valign="bottom">39.3% (n = 57)</td></tr><tr><td align="left" valign="bottom">Active smoker</td><td align="left" valign="bottom">2.8% (n = 4)</td></tr><tr><td align="left" colspan="2" valign="bottom"><bold>Acute COVID-19 severity (% cohort</bold>)</td></tr><tr><td align="left" valign="bottom">Mild: outpatient</td><td align="left" valign="bottom">24.8% (n = 36)</td></tr><tr><td align="left" valign="bottom">Moderate: inpatient without oxygen therapy</td><td align="left" valign="bottom">25.5% (n = 37)</td></tr><tr><td align="left" valign="bottom">Severe: inpatient with oxygen therapy</td><td align="left" valign="bottom">27.6% (n = 40)</td></tr><tr><td align="left" valign="bottom">Critical: intensive care unit</td><td align="left" valign="bottom">22.1% (n = 32)</td></tr><tr><td align="left" colspan="2" valign="bottom"><bold>Comorbidities (% cohort</bold>)</td></tr><tr><td align="left" valign="bottom">None</td><td align="left" valign="bottom">22.8% (n = 33)</td></tr><tr><td align="left" valign="bottom">Cardiovascular disease</td><td align="left" valign="bottom">40% (n = 58)</td></tr><tr><td align="left" valign="bottom">Pulmonary disease</td><td align="left" valign="bottom">18.6% (n = 27)</td></tr><tr><td align="left" valign="bottom">Metabolic disease</td><td align="left" valign="bottom">43.4% (n = 63)</td></tr><tr><td align="left" valign="bottom">Chronic kidney disease</td><td align="left" valign="bottom">6.9% (n = 10)</td></tr><tr><td align="left" valign="bottom">Gastrointestinal tract diseases</td><td align="left" valign="bottom">13.8% (n = 20)</td></tr><tr><td align="left" valign="bottom">Malignancy</td><td align="left" valign="bottom">11.7% (n = 17)</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Hospitalization and medication during acute COVID-19.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameter</th><th align="left" valign="bottom">Outpatient (n = 36)</th><th align="left" valign="bottom">Hospitalized (n = 37)</th><th align="left" valign="bottom">Hospitalized oxygen therapy (n = 40)</th><th align="left" valign="bottom">Hospitalized intensive care unit (n = 32)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Mean hospitalization time, days</td><td align="left" valign="bottom">0 (SD = 0)</td><td align="left" valign="bottom">6.9 (SD = 3.6)</td><td align="left" valign="bottom">11.8 (SD = 6.3)</td><td align="left" valign="bottom">34.8 (SD = 15.7)</td></tr><tr><td align="left" valign="bottom">Hospitalized &gt;7 days</td><td align="left" valign="bottom">0% (n = 0)</td><td align="left" valign="bottom">43.2% (n = 16)</td><td align="left" valign="bottom">80% (n = 32)</td><td align="left" valign="bottom">100% (n = 32)</td></tr><tr><td align="left" valign="bottom">Anti-infectives</td><td align="left" valign="bottom">11.1% (n = 4)</td><td align="left" valign="bottom">45.9% (n = 17)</td><td align="left" valign="bottom">72.5% (n = 29)</td><td align="left" valign="bottom">87.5% (n = 28)</td></tr><tr><td align="left" valign="bottom">Antiplatelet drugs</td><td align="left" valign="bottom">2.8% (n = 1)</td><td align="left" valign="bottom">10.8% (n = 4)</td><td align="left" valign="bottom">22.5% (n = 9)</td><td align="left" valign="bottom">25% (n = 8)</td></tr><tr><td align="left" valign="bottom">Anticoagulatives</td><td align="left" valign="bottom">2.8% (n = 1)</td><td align="left" valign="bottom">2.7% (n = 1)</td><td align="left" valign="bottom">5% (n = 2)</td><td align="left" valign="bottom">15.6% (n = 5)</td></tr><tr><td align="left" valign="bottom">Corticosteroids<xref ref-type="table-fn" rid="table2fn1">*</xref><xref ref-type="table-fn" rid="table2fn2">†</xref></td><td align="left" valign="bottom">2.8% (n = 1)</td><td align="left" valign="bottom">5.4% (n = 2)</td><td align="left" valign="bottom">22.5% (n = 9)</td><td align="left" valign="bottom">40.6% (n = 13)</td></tr><tr><td align="left" valign="bottom">Immunosuppression<xref ref-type="table-fn" rid="table2fn3">‡</xref><xref ref-type="table-fn" rid="table2fn2">†</xref></td><td align="left" valign="bottom">0% (n = 0)</td><td align="left" valign="bottom">2.7% (n = 1)</td><td align="left" valign="bottom">5% (n = 2)</td><td align="left" valign="bottom">9.4% (n = 3)</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>From the week 4 post diagnosis on, at the discretion of the physician.</p></fn><fn id="table2fn2"><label>†</label><p>Subsumed under ‘immunosuppression, acute COVID-19’ for data analysis.</p></fn><fn id="table2fn3"><label>‡</label><p>Immunosuppressive medication prior to COVID-19.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Radiological, functional, and clinical study outcomes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Outcome</th><th align="left" valign="bottom">60-day follow-up</th><th align="left" valign="bottom">100-day follow-up</th><th align="left" valign="bottom">180-day follow-up</th></tr></thead><tbody><tr><td align="left" valign="bottom">Any lung CT abnormalities (complete: n = 103)</td><td align="left" valign="bottom">74.8% (n = 77)</td><td align="left" valign="bottom">60.2% (n = 62)</td><td align="left" valign="bottom">48.5% (n = 50)</td></tr><tr><td align="left" valign="bottom">Mild lung CT abnormalities (severity score ≤ 5) (complete: n = 103)</td><td align="left" valign="bottom">26.2% (n = 27)</td><td align="left" valign="bottom">36.9% (n = 38)</td><td align="left" valign="bottom">29.1% (n = 30)</td></tr><tr><td align="left" valign="bottom">Moderate-to-severe CT abnormalities (severity score &gt; 5) (complete: n = 103)</td><td align="left" valign="bottom">48.5% (n = 50)</td><td align="left" valign="bottom">23.3% (n = 24)</td><td align="left" valign="bottom">19.4% (n = 20)</td></tr><tr><td align="left" valign="bottom">Functional lung impairment (complete: n = 116)</td><td align="left" valign="bottom">39.7% (n = 46)</td><td align="left" valign="bottom">37.1% (n = 43)</td><td align="left" valign="bottom">33.6% (n = 39)</td></tr><tr><td align="left" valign="bottom">Persistent symptoms (complete: n = 145)</td><td align="left" valign="bottom">79.3% (n = 115)</td><td align="left" valign="bottom">67.6% (n = 98)</td><td align="left" valign="bottom">49% (n = 71)</td></tr></tbody></table><table-wrap-foot><fn><p>CT = computed tomography.</p></fn></table-wrap-foot></table-wrap><p>In total, 190 COVID-19 patients were screened for participation. Thereof, n = 18 subjects refused to give informed consent, n = 27 declared difficulties to appear at the study follow-ups. Data of n = 145 participants were eligible for analysis (<xref ref-type="fig" rid="fig1">Figure 1</xref>). All participants gave written informed consent. The study was approved by the Institutional Review Board at the Medical University of Innsbruck (approval number: 1103/2020) and registered at ClinicalTrials.gov (NCT04416100).</p></sec><sec id="s2-2"><title>Procedures</title><p>We retrospectively assessed patient characteristics during acute COVID-19 and performed follow-up investigations at 60 days (63 ± 23 days [mean ± SD]; visit 1), 100 days (103 ± 21 days; visit 2), and 180 days (190 ± 15 days; visit 3) after diagnosis of COVID-19. Each visit included symptom and physical performance assessment with a standardized questionnaire, LF testing, standard laboratory testing, and a CT scan of the chest. The variables available for analysis with their stratification schemes are listed in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><p>Serological markers were determined in certified laboratories (Central Institute of Clinical and Chemical Laboratory Diagnostics, Rheumatology and Infectious Diseases Laboratory, both at the University Hospital of Innsbruck). C-reactive protein (CRP), interleukin-6 (IL-6), N-terminal pro natriuretic peptide (NT-proBNP), and serum ferritin were measured using a Roche Cobas 8000 analyzer. D-dimer was determined with a Siemens BCS-XP instrument using the Siemens D-Dimer Innovance reagent. Anti-S1/S2 protein SARS-CoV-2 immunoglobulin gamma (IgG) were quantified with LIAISON chemoluminescence assay (DiaSorin, Italy), expressed as binding antibody units (BAU, conversion factor = 5.7) and stratified by quartiles (<xref ref-type="bibr" rid="bib16">Ferrari et al., 2021</xref>)⁠.</p><p>Low-dose (100 kVp tube potential) craniocaudal CT scans of the chest were acquired without iodine contrast and without ECG gating on a 128-slice multidetector CT (128 × 0.6 mm collimation, 1.1 spiral pitch factor, SOMATOM Definition Flash, Siemens Healthineers, Erlangen, Germany). In case of clinically suspected pulmonary embolism, CT scans were performed with a contrast agent. Axial reconstructions were done with 1 mm slices. CT scans were evaluated for ground-glass opacities, consolidations, bronchial dilation, and reticulations as defined by the Fleischner Society. Lung findings were graded with a semi-quantitative CT severity score (0–25 points) (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>)⁠.</p><p>Impaired LF was defined as (1) forced vital capacity (FVC) &lt; 80% or (2) forced expiratory volume in 1 s (FEV<sub>1</sub>) &lt; 80%, or (3) FEV<sub>1</sub>:FVC &lt; 70% or (4) total lung capacity (TLC) &lt; 80% or (5) diffusing capacity of carbon monoxide (DLCO) &lt; 80% predicted.</p></sec><sec id="s2-3"><title>Statistical analysis</title><p>Statistical analyses were performed with R version 4.0.5 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Data transformation and visualization were accomplished by <italic>tidyverse</italic> (<xref ref-type="bibr" rid="bib56">Wickham et al., 2019</xref>)⁠, <italic>ggplot2</italic> (<xref ref-type="bibr" rid="bib55">Wickham, 2016</xref>)⁠, <italic>ggvenn</italic>, <italic>plotROC</italic> (<xref ref-type="bibr" rid="bib41">Sachs, 2017</xref>),⁠ and <italic>cowplot</italic> (<xref ref-type="bibr" rid="bib58">Wilke, 2019</xref>)⁠ packages. The recorded variables were binarized as shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. Acute COVID-19 severity strata were defined as presented in <xref ref-type="table" rid="table1">Table 1</xref>. p-Values were corrected for multiple comparisons with the Benjamini–Hochberg method (<xref ref-type="bibr" rid="bib4">Benjamini and Hochberg, 1995</xref>), and effects were termed significant for p&lt;0.05.</p></sec><sec id="s2-4"><title>Variable overlap, kinetics, and risk modeling</title><p>Overlap between the 180-day follow-up outcome features was assessed by analysis of quasi-proportional Venn plots (package <italic>nVennR</italic>) (<xref ref-type="bibr" rid="bib37">Pérez-Silva et al., 2018</xref>)⁠ and calculation of the Cohen’s κ statistic (package <italic>vcd</italic>) (<xref ref-type="bibr" rid="bib17">Fleiss et al., 1969</xref>)⁠. Kinetics of binary outcome variables in participants subsets with the complete longitudinal data record was modeled with mixed-effect logistic regression (random effect: individual, fixed effect: time, packages <italic>lme4</italic> [<xref ref-type="bibr" rid="bib2">Bates et al., 2015</xref>]⁠ and <italic>lmerTest</italic> [<xref ref-type="bibr" rid="bib29">Kuznetsova et al., 2017</xref>]⁠). Analyses in the severity groups were done with separate models. Significance was assessed by the likelihood ratio test (LRT) against the random-term-only model. Univariate risk modeling was performed with fixed-effect logistic regression (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). Odds ratio (OR) significance was determined by Wald Z test. In-house-developed linear modeling wrappers around base R tools are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/lmqc">https://github.com/PiotrTymoszuk/lmqc</ext-link>.</p></sec><sec id="s2-5"><title>Cluster analysis</title><p>Clustering of non-CT and non-LF binary clinical features (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) was accomplished with PAM algorithm (partitioning around medoids, package <italic>cluster</italic>) (<xref ref-type="bibr" rid="bib1">Amato et al., 2019</xref>)⁠ and simple matching distance (SMD, package <italic>nomclust</italic>) (<xref ref-type="bibr" rid="bib5">Boriah et al., 2008</xref>)⁠. Association analysis for the participants was performed with a combined procedure involving clustering of the observations by the self-organizing map algorithm (SOM, 4 × 4 hexagonal grid, SMD distance, <italic>kohonen</italic> package), followed by clustering of the SOM nodes by the Ward.D2 hierarchical clustering algorithm (Euclidean distance, <italic>hclust</italic>() function, package <italic>stats</italic>) (<xref ref-type="bibr" rid="bib50">Vesanto and Alhoniemi, 2000</xref>; <xref ref-type="bibr" rid="bib27">Kohonen, 1995</xref>; <xref ref-type="bibr" rid="bib52">Wehrens and Kruisselbrink, 2018</xref>)⁠. Clustering analyses were performed in the participant subset with the complete set of clustering variables. The selection of the optimal clustering algorithm was motivated by the highest ratio of between-cluster to total variance and the best stability measured by mean classification error in 20-fold cross-validation (CV) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and B</xref>; <xref ref-type="bibr" rid="bib31">Lange et al., 2004</xref>)⁠. The optimal cluster number was determined by the bend of the within-cluster sum-of-squares curve (function <italic>fviz_nbclust</italic>(), package <italic>factoextra</italic>) and by the stability in 20-fold CV (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D and F</xref>; <xref ref-type="bibr" rid="bib31">Lange et al., 2004</xref>; <xref ref-type="bibr" rid="bib51">Wang, 2010</xref>)⁠, as well as by a visual inspection of the SOM node clustering dendrograms (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>). Assignment of 180-day follow-up outcome features to the clusters of clinical parameters was accomplished with a k-nearest neighbor (kNN) label propagation algorithm (<xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>; <xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Leng et al., 2013</xref>)⁠. Cluster assignment visualization in a four-dimensional principal analysis score plot was done with the <italic>PCAproj</italic>() tool (package <italic>pcaPP</italic>) (<xref ref-type="bibr" rid="bib8">Croux et al., 2007</xref>)⁠. To determine the importance of particular clustering variables, the variance (between-cluster to total variance ratio) between the initial cluster structure and the structure with random resampling of the variable was compared, as initially proposed for the random forests ML classifier (<xref ref-type="bibr" rid="bib6">Breiman, 2001</xref>)⁠. Frequencies of the outcome events in the participant clusters were compared with χ<sup>2</sup> test. In-house-developed association analysis wrappers are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/clustering-tools-2">https://github.com/PiotrTymoszuk/clustering-tools-2</ext-link>.</p></sec><sec id="s2-6"><title>Machine learning</title><p>ML classifiers C5.0 (package <italic>C50</italic>) (<xref ref-type="bibr" rid="bib38">Quinlan, 1993</xref>)⁠, random forests (<italic>randomForest</italic>) (<xref ref-type="bibr" rid="bib6">Breiman, 2001</xref>)⁠, support vector machines with radial kernel (<italic>kernlab</italic>) (<xref ref-type="bibr" rid="bib53">Weston and Watkins, 1998</xref>)⁠, neural networks (<italic>nnet</italic>) (<xref ref-type="bibr" rid="bib40">Ripley, 2014</xref>)⁠, and elastic net (<italic>glmnet</italic>) (<xref ref-type="bibr" rid="bib18">Friedman et al., 2010</xref>)⁠ were trained to predict the 180-day follow-up outcomes employing non-CT and non-LF binary explanatory features (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). The ML training was performed in the participant subsets with the complete set of explanatory and outcome variables. The training, optimization, and CV (20-fold, five repetitions) were accomplished by the <italic>train</italic>() tool from <italic>caret</italic> package, with the Cohen’s κ statistic as a model selection metric (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>; <xref ref-type="bibr" rid="bib28">Kuhn, 2008</xref>)⁠. Classifier ensembles were constructed with the elastic net procedure (<italic>caretStack</italic>() function, <italic>caretEnsemble</italic> package, <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>; <xref ref-type="bibr" rid="bib10">Deane-Mayer and Knowles, 2019</xref>)⁠. Classifier performance in the training cohort and CV was assessed by receiver-operating characteristics (ROCs), Cohen’s κ and accuracy (packages <italic>caret</italic> and <italic>vcd,</italic> <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>; <xref ref-type="bibr" rid="bib17">Fleiss et al., 1969</xref>; <xref ref-type="bibr" rid="bib28">Kuhn, 2008</xref>)<bold>⁠</bold>. Variable importance measures were extracted from the C5.0 (percent variable usage, <italic>c5imp</italic>() function, package <italic>C50</italic>) (<xref ref-type="bibr" rid="bib38">Quinlan, 1993</xref>)⁠, random forests (Δ Gini index, <italic>importance</italic>(), package <italic>randomForest</italic>) (<xref ref-type="bibr" rid="bib6">Breiman, 2001</xref>)⁠, and elastic net classifiers (regression coefficient β, <italic>coef</italic>(), package <italic>glmnet</italic>) (<xref ref-type="bibr" rid="bib18">Friedman et al., 2010</xref>)⁠.</p></sec><sec id="s2-7"><title>Pulmonary recovery assessment app</title><p>Participant clustering and ML classifiers trained in the CovILD cohort were implemented in an open-source online pulmonary assessment R shiny app (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>; code: <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app">https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app</ext-link>). Prediction of the cluster assignment based on the user-provided patient data is done by the kNN label propagation algorithm (<xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Leng et al., 2013</xref>)⁠.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Patient characteristics</title><p>The CovILD study participants (n = 145) were predominantly male (57.8%), age ranging between 19 and 87 years. 77.2% of participants displayed preexisting comorbidity, predominantly cardiovascular and metabolic disease. The cohort included mild (outpatient care, 24.8%), moderate (hospitalization without oxygen supply, 25.5%), severe (hospitalization with oxygen supply, 27.6%), and critical (intensive care unit [ICU] treatment, 22.1%) cases of acute COVID-19 (<xref ref-type="table" rid="table1">Table 1</xref>). The majority of hospitalized participants received anti-infectives during acute COVID-19, anticoagulative, and/or antiplatelet treatment introduced primarily in the ventilated patients. Systemic steroid administration was initiated at the discretion of the physician beginning from week 4 after diagnosis (<xref ref-type="table" rid="table2">Table 2</xref>).</p></sec><sec id="s3-2"><title>Clinical recovery after COVID-19</title><p>Most patients, irrespective of the acute COVID-19 severity, showed a significant resolution of disease symptoms over time (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Persistent complaints at the 6-month follow-up were reported by 49% of the study subjects (<xref ref-type="table" rid="table3">Table 3</xref>), with self-reported impaired physical performance (34.7%), sleep disorders (27.1%), and exertional dyspnea (22.8%) as leading manifestations. The frequency of all investigated symptoms declined significantly, even though the pace of their resolution was remarkably slower in the late (100- and 180-day follow-ups) than in the early recovery phase (acute COVID-19 till 60-day follow-up) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study inclusion flow diagram and analysis scheme.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig1-v2.tif"/></fig><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Kinetic of recovery from COVID-19 symptoms.</title><p>Recovery from any COVID-19 symptoms was investigated by mixed-effect logistic modeling (random effect: individual; fixed effect: time). Significance was determined by the likelihood ratio test corrected for multiple testing with the Benjamini–Hochberg method, and p-values and the numbers of complete observations are indicated in the plots. (<bold>A</bold>) Frequencies of individuals with any symptoms in the study cohort stratified by acute COVID-19 severity. (<bold>B</bold>) Frequencies of participants with particular symptoms. imp.: impaired.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig2-v2.tif"/></fig><p>Impaired LF was observed in 33.6% of the participants at the 6-month follow-up (<xref ref-type="table" rid="table3">Table 3</xref>). Except for the critical COVID-19 survivors (60 days: 66.7%; 180 days post-COVID-19: 50%), no significant reduction in the frequency of LF impairment over time was observed (<xref ref-type="fig" rid="fig3">Figure 3</xref>). At the 6-month follow-up, structural lung abnormalities were found in 48.5% of patients and moderate-to-severe radiological lung alterations (CT severity score &gt; 5) were present in 19.4% of participants (<xref ref-type="table" rid="table3">Table 3</xref>). The majority of the participants with impaired LF displayed radiological lung findings. However, a substantial fraction of CT abnormalities, especially mild ones, were accompanied neither by persistent symptoms nor by LF deficits (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref><bold>,</bold> <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Kinetic of pulmonary recovery.</title><p>Recovery from any lung computed tomography (CT) abnormalities, moderate-to-severe lung CT abnormalities (severity score &gt; 5), and recovery from functional lung impairment were investigated in the participants stratified by acute COVID-19 severity by mixed-effect logistic modeling (random effect: individual; fixed effect: time). Significance was determined by the likelihood ratio test corrected for multiple testing with the Benjamini–Hochberg method. Frequencies of the given abnormality at the indicated time points are presented, and p-values and the numbers of complete observations are indicated in the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Co-occurrence of lung computed tomography (CT) abnormalities, functional lung impairment, and any persistent symptoms.</title><p>Numbers and percentages of the study participants with any persistent symptoms, functional lung impairment, or lung CT abnormalities at the consecutive follow-up visits presented in quasi-proportional Venn diagrams. The numbers of participants with CT abnormalities, lung function (LF) impairment, and persistent symptoms are indicated in the diagrams, and the numbers of complete observations are shown under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Co-occurrence of moderate-to-severe lung computed tomography (CT) abnormalities, functional lung impairment, and any persistent symptoms.</title><p>Numbers and percentages of the study participants with any persistent symptoms, functional lung impairment, or moderate-to-severe lung CT abnormalities (severity score &gt; 5) at the consecutive follow-up visits presented in quasi-proportional Venn diagrams. The numbers of participants with CT abnormalities, lung function (LF) impairment, and persistent symptoms are indicated in the diagrams, and the numbers of complete observations are shown under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Frequency of mild and moderate-to-severe lung computed tomography (CT) abnormalities.</title><p>Prognostic value of functional lung impairment and persistent symptoms for prediction of radiological lung abnormalities. (<bold>A</bold>) Relevance of functional lung impairment and persistent COVID-19 symptoms at predicting any lung CT abnormalities and moderate-to-severe lung CT abnormalities (severity score &gt; 5) at the consecutive follow-up visits. The concordance of the outcome variables was determined by Cohen’s κ coefficient. Statistical significance (κ ̸ = 0) was assessed by two-tailed <italic>t</italic>-test corrected for multiple testing with the Benjamini–Hochberg method. Kappa with 95% confidence intervals and p values are presented as a heat map. The number of complete observations is indicated in the plot. (<bold>B</bold>) Percentages of mild (severity score ≤ 5) and moderate-to-severe lung CT abnormalities at the consecutive follow-up visits in the study participants stratified by the severity of acute COVID-19. Statistical significance of frequency differences was determined by χ<sup>2</sup> test for trend corrected for multiple testing with the Benjamini–Hochberg method. The number of complete observations is indicated under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig3-figsupp3-v2.tif"/></fig></fig-group><p>The frequency, scoring, and recovery of CT lung findings were related to the severity of acute infection. Pulmonary lesions scored &gt; 5 CT severity points at the 180-day follow-up were most frequent in the individuals with severe and critical acute COVID-19 (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Notably, the hospitalized group with oxygen therapy demonstrated the fastest recovery kinetics. As for the symptom resolution, LF and CT lung recovery decelerated in the late phase of COVID-19 convalescence (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="s3-3"><title>Risk factors of protracted recovery</title><p>To identify risk factors of delayed recovery at the 6-month follow-up, we screened a set of 52 binary clinical parameters (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) recorded during acute COVID-19 and at the 60-day visit by univariate modeling (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). By this means, no significant correlates for long-term symptom persistence were identified. Risk factors and readouts of severe and critical COVID-19 including multimorbidity, malignancy, male sex, prolonged hospitalization, ICU stay, and immunosuppressive therapy were significantly associated with persistent CT (<xref ref-type="fig" rid="fig4">Figure 4</xref>) and LF abnormalities (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Persistently elevated inflammatory markers, IL-6 (&gt;7 ng/L) and CRP (&gt;0.5 mg/L), were strong unfavorable risk factors for incomplete radiological and functional pulmonary recovery. Additionally, the biochemical readout of microvascular inflammation, D-dimer (&gt;500 pg/mL) was significantly linked to LF deficits. Low serum anti-S1/S2 IgG titers at the 60-day follow-up and ambulatory acute COVID-19 correlated with an improved pulmonary recovery (<xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig5">5</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Risk factors of persistent radiological lung abnormalities.</title><p>Association of 52 binary explanatory variables (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) with the presence of any lung computed tomography (CT) abnormalities (<bold>A</bold>) or moderate-to-severe lung CT abnormalities (severity score &gt; 5) (<bold>B</bold>) at the 180-day follow-up visit was investigated with a series of univariate logistic models (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). Odds ratio (OR) significance was determined by Wald Z test and corrected for multiple testing with the Benjamini–Hochberg method. ORs with 95% confidence intervals for significant favorable and unfavorable factors are presented in forest plots. Model baseline (ref) and numbers of complete observations are presented in the plot axis text. Q1, Q2, Q3, Q4: first, second, third, and fourth quartile of anti-S1/S2 IgG titer; ICU: intensive care unit.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig4-v2.tif"/></fig><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Risk factors of persistent functional lung impairment.</title><p>Association of 52 binary explanatory variables (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) with the presence of functional lung impairment at the 180-day follow-up visit was investigated with a series of univariate logistic models (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). Odds ratio (OR) significance was determined by Wald Z test and corrected for multiple testing with the Benjamini–Hochberg method. ORs with 95% confidence intervals for the significant favorable and unfavorable factors are presented in a forest plot. Model baseline (ref) and n numbers of complete observations are presented in the plot axis text. Q1, Q2, Q3, Q4: first, second, third, and fourth quartile of anti-S1/S2 IgG titer; CKD: chronic kidney disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig5-v2.tif"/></fig></sec><sec id="s3-4"><title>Clusters of clinical features linked to persistent symptoms and lung abnormalities</title><p>Employing the unsupervised PAM algorithm (<xref ref-type="bibr" rid="bib1">Amato et al., 2019</xref>)⁠, three clusters of co-occurring non-CT and non-LF clinical features of acute COVID-19 and early convalescence (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) were identified (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>): (1) cluster 1 with male sex, hypertension, and cardiovascular and metabolic comorbidity; (2) cluster 2, including characteristics of acute COVID-19 severity and inflammatory markers; and (3) cluster 3 consisting of acute and persistent COVID-19 symptoms (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>, <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>).</p><p>The 6-month follow-up outcome variables were incorporated in the cluster structure using kNN prediction (<xref ref-type="bibr" rid="bib32">Leng et al., 2013</xref>)⁠. Long-term symptom persistence was associated with acute and long-lasting COVID-19 symptoms in cluster 3, whereas pulmonary outcome parameters were grouped with cluster 2 features (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>, <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>). Preexisting comorbidities such as malignancy, kidney, lung and gastrointestinal disease, obesity, and diabetes were found the closest cluster neighbors of mild CT abnormalities (severity score ≤ 5). Moderate-to-severe structural alterations (severity score &gt; 5) and LF deficits were, in turn, tightly linked to markers of protracted systemic inflammation (IL-6, CRP, anemia of inflammation) (<xref ref-type="bibr" rid="bib44">Sonnweber et al., 2020</xref>;⁠ <xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Association of incomplete symptom, lung function, and radiological lung recovery with demographic and clinical parameters of acute COVID-19 and early recovery.</title><p>Clustering of 52 non-computed tomography (non-CT) and non-lung function binary explanatory variables recorded for acute COVID-19 or at the early 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) was investigated by partitioning around medoids (PAM) algorithm with simple matching distance (SMD) dissimilarity measure (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>). The cluster assignment for the outcome variables at the 180-day follow-up visit (persistent symptoms, functional lung impairment, mild lung CT abnormalities [severity score ≤ 5] and moderate-to-severe lung CT abnormalities [severity score &gt; 5]) was predicted by k-nearest neighbor (kNN) label propagation procedure. Numbers of complete observations and numbers of features in the clusters are indicated in (<bold>A</bold>). (<bold>A</bold>) Cluster assignment of the outcome variables (diamonds) presented in the plot of principal component (PC) scores. The first two major PCs are displayed. The explanatory variables are visualized as points. Percentages of the data set variance associated with the PC are presented in the plot axes. (<bold>B</bold>) Five nearest neighbors (lowest SMD) of the outcome variables presented in radial plots. Font size, point radius, and color code for SMD values. Q1, Q2, Q3, Q4: first, second, third, and fourth quartile of anti-S1/S2 IgG titer; GITD: gastrointestinal disease; CKD: chronic kidney disease; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Study feature clustering algorithm.</title><p>Clustering of 52 non-computed tomography (non-CT) and non-lung function binary explanatory variables recorded for acute COVID-19 or at the early 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). (<bold>A, B</bold>) Comparison of ‘explained’ variances (between-cluster to total sum-of-squares ratio) (<bold>A</bold>) and cluster stability (mean classification error in 20-fold cross-validation) (<bold>B</bold>) in clustering of the data set with several algorithms with k = 3 centers/branches (algorithms: K-means; PAM: partitioning around medoids; HCl Ward.D2: hierarchical clustering with Ward.D2 method; distances: SMD: simple matching distance; Jaccard, Dice, and Cosine). (<bold>C, D</bold>) The optimal number of the feature clusters in clustering with the optimally performing PAM algorithm with SMD dissimilarity measure was determined by the bend of the total within-cluster sum-of-squares curve (<bold>C</bold>) and confirmed by good stability (low mean classification error) in 20-fold cross-validation (<bold>D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Semi-supervised clustering of mild and moderate-to-severe lung computed tomography (CT) abnormalities, functional lung impairment, and persistent symptoms at the 180-day follow-up with parameters of acute COVID-19 and early convalescence.</title><p>Clusters of 52 non-CT and non-lung function binary explanatory variables recorded for acute COVID-19 or at the 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) were defined by the optimally performing partitioning around medoids (PAM) algorithm and simple matching distance (SMD) dissimilarity measure (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>). The cluster assignment for the outcome variables at the 180-day follow-up visit (persistent symptoms, functional lung impairment, mild lung CT abnormalities [severity score ≤ 5], and moderate-to-severe lung CT abnormalities [severity score &gt; 5]) was predicted by k-nearest neighbor (kNN) label propagation procedure. SMD between the features and their cluster assignments are shown in a heat map. The numbers of features in the clusters and the total number of observations are indicated under the plot. CVD: cardiovascular disease; Q1, Q2, Q3, Q4: first, second, third, and fourth quartile of anti-S1/S2 IgG titer; GI: gastrointestinal; PD: pulmonary disease; GITD: gastrointestinal disease; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig6-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s3-5"><title>Risk stratification for perturbed pulmonary recovery by unsupervised clustering</title><p>Next, we tested whether subsets of patients at risk of an incomplete 6-month recovery may be defined by a similar clustering procedure employing exclusively non-CT and non-LF clinical variables (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Applying a combined SOM – hierarchical clustering approach, three clusters of the study participants were identified (<xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib50">Vesanto and Alhoniemi, 2000</xref>; <xref ref-type="bibr" rid="bib27">Kohonen, 1995</xref>)⁠. Prolonged hospitalization, anti-infective therapy, overweight or obesity, pain during acute COVID-19, and low anti-S1/S2 titers at the 60-day follow-up were found the most influential clustering features (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib6">Breiman, 2001</xref>)⁠. The patient subsets identified by the SOM approach differed significantly in frequency of radiological lung abnormalities and substantially, yet not significantly, in the frequency of LF impairment at the 180-day follow-up. In particular, most of the individuals assigned to the largest, low-risk (LR) subset were CT and LF abnormality-free. The frequency and severity of radiological pulmonary findings were elevated in the smallest intermediate-risk subset (IR) and peaked in the high-risk (HR) group (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Despite a comparable frequency of long-term symptoms between the LR, IR, and HR subsets (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), the HR collective showed the lowest prevalence of dyspnea, cough, night sweating, pain, gastrointestinal manifestations, and complete absence of hyposmia at the 180-day follow-up (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Although the LR subset primarily comprised mild COVID-19 cases and the HR subset ICU survivors, the cluster assignment (IR vs. LR, HR vs. LR) remained an independent correlate of persistent CT and LF abnormalities after adjustment for the acute COVID-19 severity (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Clustering of the study participants by non-lung function and non-computed tomography (non-CT) clinical features.</title><p>Study participants (n = 133 with the complete variable set) were clustered with respect to 52 non-CT and non-lung function binary explanatory variables recorded for acute COVID-19 or at the 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) using a combined self-organizing map (SOM: simple matching distance) and hierarchical clustering (Ward.D2 method, Euclidean distance) procedure (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). The numbers of participants assigned to low-risk (LR), intermediate-risk (IR), and high-risk (HR) clusters are indicated in (<bold>A</bold>). (<bold>A</bold>) Cluster assignment of the study participants in the plot of principal component (PC) scores. The first two major PCs are displayed. Percentages of the data set variance associated with the PC are presented in the plot axes. (<bold>B</bold>) Presence of the most influential clustering features (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>) in the participant clusters presented as a heat map. Cluster #1, #2, and #3 refer to the feature clusters defined in <xref ref-type="fig" rid="fig6">Figure 6</xref>. Q1, Q2, Q3, Q4: first, second, third, and fourth quartile of anti-S1/S2 IgG titer; GITD: gastrointestinal disease; CKD: chronic kidney disease; CVD: cardiovascular disease; GI: gastrointestinal; PD: pulmonary disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Study participant clustering algorithm.</title><p>Clustering of the study participants (n = 133 with the complete variable set) with respect to 52 non-computed tomography (non-CT) and non-lung function binary explanatory variables recorded for acute COVID-19 or at the 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). The procedure involved clustering of the observations with self-organizing maps (SOM, 4 × 4 hexagonal grid, distances: SMD: simple matching distance, Jaccard, Dice, or Cosine) followed by clustering of the SOM nodes (algorithms: HCl ward.D2: hierarchical clustering with Ward.D2 method; K-means; PAM: partitioning around medoids; distance: Euclidean). Different combinations of observation dissimilarity measures and SOM node clustering algorithms were tested in the search for the optimal clustering algorithm. (<bold>A, B</bold>) Comparison of ‘explained’ variances (between-cluster to total sum-of-squares ratio) (<bold>A</bold>) and cluster stability (mean classification error in 20-fold cross-validation) (<bold>B</bold>) in clustering of the data set with different observation distance measures and SOM node clustering algorithms. (C) Training of the SOM algorithm, mean distance to the winning un as a function of lgorithm iterations is presented. Note the mean distance plateau indicative of the algorithm convergence (<bold>D–F</bold>) The optimal number of the SOM node clusters in clustering with the optimally performing SOM HCl algorithm with SMD observation dissimilarity measure. The optimal cluster number was determined by the bend of the total within-cluster sum-of-squares curve (D) and confirmed by visual inspection of the HCl dendrogram (<bold>E</bold>) and good stability (low mean classification error) in 20-fold cross-validation (F).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Impact of specific variables on the quality of participant clustering.</title><p>The clusters of participants clusters were defined with the optimally performing self-organizing map (SOM)/HCl algorithm with simple matching distance (SMD) observation dissimilarity measure as presented in <xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>. The impact of a particular clustering variable was determined by comparing the ‘explained’ clustering variance (between-cluster to total sum-of-squares ratio) between the initial cluster structure and the structure with random resampling of the variable. Differences in the clustering variances for the most influential clustering variables (Δ clustering variance &gt; 0) are presented in the plot. Q1, Q3: first, third quartile of anti-S1/S2 IgG titer; CKD: chronic kidney disease; GI: gastrointestinal; CVD: cardiovascular disease; PD: pulmonary disease; GITD: gastrointestinal disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig7-figsupp2-v2.tif"/></fig></fig-group><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Frequency of persistent radiological lung abnormalities, functional lung impairment, and symptoms in the participant clusters.</title><p>The clusters of study participants were defined by non-lung function and non-computed tomography (non-CT) features as presented in <xref ref-type="fig" rid="fig7">Figure 7</xref>. Frequencies of outcome variables at the 180-day follow-up visit (mild [severity score ≤ 5], moderate-to-severe lung CT abnormalities [severity score &gt; 5], functional lung impairment, and persistent symptoms) were compared between the low-risk (LR), intermediate-risk (IR), and high-risk (HR) participant clusters by χ<sup>2</sup> test corrected for multiple testing with the Benjamini–Hochberg method. p-Values and numbers of participants assigned to the clusters are indicated in the plots. (<bold>A</bold>) Frequencies of the outcome features in the participant clusters. (<bold>B</bold>) Frequencies of specific symptoms in the participant clusters.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Risk of radiological lung abnormalities at the 180-day follow-up in the participant clusters.</title><p>The clusters of participants were defined by non-lung function and non-computed tomography (non-CT) clinical features of acute COVID-19 and early convalescence (60-day follow-up visit, <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) with the optimally performing HCl algorithm with simple matching distance (SMD) observation dissimilarity measure as presented in <xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>. (<bold>A</bold>) Distribution of mild, moderate, severe, and critical acute COVID-19 cases in the participant clusters. Significance of the distribution differences was assessed with χ<sup>2</sup> test. The numbers of participants assigned to the clusters are indicated under the plot. (<bold>B</bold>) Association of the participant cluster assignment (LR: low-risk; IR: intermediate-risk; HR: high-risk cluster) with the risk of any lung CT abnormalities and moderate-to-severe lung CT abnormalities (severity score &gt; 5) at the 180-day follow-up visit was investigated by logistic modeling with and without inclusion of the acute COVID-19 severity effect (severity-adjusted). Odds ratio (OR) significance was determined by Wald Z test and corrected for multiple testing with the Benjamini–Hochberg method. ORs with 95% confidence intervals are presented in forest plots. Numbers of complete observations, outcome events, participants in the clusters, and the acute COVID-19 severity subsets are indicated under the plot.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig8-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s3-6"><title>Prediction of persistent symptoms and pulmonary abnormalities by machine learning</title><p>Finally, we investigated if the 6-month follow-up outcome may be predicted by ML classifiers trained with a set of non-CT and non-LF variables recorded during acute COVID-19 and at the 60-day follow-up (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). To this end, five technically unrelated ML classifiers were tested (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>; <xref ref-type="bibr" rid="bib28">Kuhn, 2008</xref>)⁠: C5.0 (<xref ref-type="bibr" rid="bib38">Quinlan, 1993</xref>)⁠, random forests (RF) (<xref ref-type="bibr" rid="bib6">Breiman, 2001</xref>)⁠, support vector machines with radial kernel (SVM-R) (<xref ref-type="bibr" rid="bib53">Weston and Watkins, 1998</xref>)⁠, shallow neural network (Nnet) (<xref ref-type="bibr" rid="bib40">Ripley, 2014</xref>)⁠, and elastic net generalized linear regression (glmNet) (<xref ref-type="bibr" rid="bib18">Friedman et al., 2010</xref>)⁠. In addition, the single classifiers with varying outcome-specific accuracy (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>) were bundled into ensembles by the elastic net procedure (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref>, <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>; <xref ref-type="bibr" rid="bib28">Kuhn, 2008</xref>; <xref ref-type="bibr" rid="bib10">Deane-Mayer and Knowles, 2019</xref>)⁠. Finally, the classifier and ensemble performance was investigated in the training cohort and 20-fold CV by ROC (<xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>).</p><p>All tested ML algorithms and ensembles demonstrated good accuracy (area under the curve [AUC] &gt; 0.78) and sensitivity (&gt;0.84) at predicting any lung CT abnormalities at the 6-month follow-up in the study cohort serving as a training data set. Their efficiency in CV was moderate (AUC: 0.69–0.81; sensitivity: 0.69–0.78) (<xref ref-type="fig" rid="fig9">Figure 9</xref>, <xref ref-type="fig" rid="fig9s3">Figure 9—figure supplement 3</xref>, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). In turn, moderate-to-severe structural lung findings were recognized with markedly lower sensitivity both in the training data set (&gt;0.43) and the CV (0.39–0.48). Even though impaired LF and persistent symptoms were common at the 6-month follow-up in the training data set (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>), nearly half of the cases were not identified by any of the tested ML algorithms and their ensembles in the CV setting (<xref ref-type="fig" rid="fig9">Figure 9</xref>, <xref ref-type="fig" rid="fig9s3">Figure 9—figure supplement 3</xref>, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). The sensitivity of the ensembles and single classifiers at predicting CT and LF abnormalities was substantially better in severe and critical COVID-19 survivors than in ambulatory and moderate cases (<xref ref-type="fig" rid="fig10">Figure 10</xref>, <xref ref-type="table" rid="app1table6">Appendix 1—table 6</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Prediction of persistent radiological lung abnormalities, functional lung impairment, and symptoms by machine learning algorithms.</title><p>Single machine learning classifiers (C5.0; RF: random forests; SVM-R: support vector machines with radial kernel; NNet: neural network; glmNet: elastic net) and their ensemble (Ens) were trained in the cohort data set with 52 non-computed tomography (non-CT) and non-lung function binary explanatory variables recorded for acute COVID-19 or at the 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) for predicting outcome variables at the 180-day follow-up visit (any lung CT abnormalities, moderate-to-severe lung CT abnormalities [severity score &gt; 5], functional lung impairment, and persistent symptoms) (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>). The prediction accuracy was verified by repeated 20-fold cross-validation (five repeats). Receiver-operating characteristics (ROCs) of the algorithms in the cross-validation are presented: area under the curve (AUC), sensitivity (Sens), and specificity (Spec) (<xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). The numbers of complete observations and outcome events are indicated under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Correlation of the machine learning algorithm prediction accuracy.</title><p>Machine learning classifiers (C5.0; RF: random forests; SVM-R: support vector machines with radial kernel; NNet: neural network; glmNet: elastic net) were trained in the cohort data set with 52 non-computed tomography (non-CT) and non-lung function binary explanatory variables recorded for acute COVID-19 or at the early 60-day follow-up visit (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) for predicting outcome variables at the 180-day follow-up visit (any lung CT abnormalities, moderate-to-severe lung CT abnormalities [severity score &gt; 5], functional lung impairment, and persistent symptoms) (<xref ref-type="fig" rid="fig9">Figure 9</xref>, <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>). The prediction accuracy was verified by repeated 20-fold cross-validation (five repeats). Pearson’s correlation coefficients of the classifier prediction accuracy in the cross-validation are presented as heat maps. Numbers of complete observations and outcome events are indicated under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>Machine learning model ensembles.</title><p>Single machine learning classifiers (C5.0; RF: random forests; SVM-R: support vector machines with radial kernel; NNet: neural network; glmNet: elastic net) were trained as shown in <xref ref-type="fig" rid="fig9">Figure 9</xref>. The model ensembles based on the single classifiers were constructed with the glmNet procedure (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>). glmNet regression coefficients (β) are presented in the plots. Point and text color correspond to the β value. Numbers of complete observations and outcome events are indicated under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp2-v2.tif"/></fig><fig id="fig9s3" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 3.</label><caption><title>Prediction of persistent radiological lung abnormalities, functional lung impairment, and symptoms by machine learning algorithms in the training data sets.</title><p>Single machine learning classifiers (C5.0; RF: random forests; SVM-R: support vector machines with radial kernel; NNet: neural network; glmNet: elastic net) and their ensembles were trained as shown in <xref ref-type="fig" rid="fig9">Figure 9</xref>. Performance of the classifiers in the training data sets was investigated by receiver-operating characteristic (ROC) of the algorithms (AUC: area under the curve; Sens: sensitivity; Spec: specificity, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). Numbers of complete observations and outcome events are indicated under the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp3-v2.tif"/></fig><fig id="fig9s4" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 4.</label><caption><title>Variable importance statistics for prediction of lung computed tomography (CT) abnormalities at the 180-day follow-up by machine learning classifiers.</title><p>C5.0, random forests (RF), and elastic net (glmNet) classifiers were trained as presented in <xref ref-type="fig" rid="fig9">Figure 9</xref> for prediction of any lung CT abnormalities at the 180-day follow-up visit. Variable importance measures (C5.0: % attribute/variable usage in the tree model (<bold>A</bold>); RF: difference in Gini index (<bold>B</bold>); glmNet: absolute value of the regression coefficient β (<bold>C</bold>)) for the 10 most influential explanatory variables are presented. CKD: chronic kidney disease; Q1, Q4: first, fourth quartile of anti-S1/S2 IgG titer; PD: pulmonary disease; CKD: chronic kidney disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp4-v2.tif"/></fig><fig id="fig9s5" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 5.</label><caption><title>Variable importance statistics for prediction of moderate-to-severe lung computed tomography (CT) abnormalities at the 180-day follow-up by machine learning classifiers.</title><p>C5.0, random forests (RF), and elastic net (glmNet) classifiers were trained as presented in <xref ref-type="fig" rid="fig9">Figure 9</xref> for prediction of moderate-to-severe lung CT abnormalities (severity score &gt; 5) at the 180-day follow-up visit. Variable importance measures (C5.0: % attribute/variable usage in the tree model (<bold>A</bold>); RF: difference in Gini index (<bold>B</bold>); glmNet: absolute value of the regression coefficient β (<bold>C</bold>)) for the 10 most influential explanatory variables are presented. PD: pulmonary disease; GITD: gastrointestinal disease; Q1, Q2, Q4: first, second, fourth quartile of anti-S1/S2 IgG titer.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp5-v2.tif"/></fig><fig id="fig9s6" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 6.</label><caption><title>Variable importance statistics for prediction of functional lung impairment at the 180-day follow-up by machine learning classifiers.</title><p>C5.0, random forests (RF), and elastic net (glmNet) classifiers were trained as presented in <xref ref-type="fig" rid="fig9">Figure 9</xref> for prediction of functional lung impairment at the 180-day follow-up visit. Variable importance measures (C5.0: % attribute/variable usage in the tree model (<bold>A</bold>); RF: difference in Gini index (<bold>B</bold>); glmNet: absolute value of the regression coefficient β (<bold>C</bold>)) for the 10 most influential explanatory variables are presented. CKD: chronic kidney disease; Q1, Q2: first. second quartile of anti-S1/S2 IgG titer.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp6-v2.tif"/></fig><fig id="fig9s7" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 7.</label><caption><title>Variable importance statistics for prediction of persistent symptoms at the 180-day follow-up by machine learning classifiers.</title><p>C5.0, random forests (RF), and elastic net (glmNet) classifiers were trained as presented in <xref ref-type="fig" rid="fig9">Figure 9</xref> for prediction of persistent symptoms at the 180-day follow-up visit. Variable importance measures (C5.0: % attribute/variable usage in the tree model (<bold>A</bold>); RF: difference in Gini index (<bold>B</bold>); glmNet: absolute value of the regression coefficient β (<bold>C</bold>)) for the 10 most influential explanatory variables are presented. CVD: cardiovascular disease; GITD: gastrointestinal disease; COPD: chronic obstructive lung disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig9-figsupp7-v2.tif"/></fig></fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Performance of the machine learning ensemble classifier in mild-to-moderate and severe-to-critical COVID-19 convalescents.</title><p>The machine learning classifier ensemble (Ens) was developed as presented in <xref ref-type="fig" rid="fig9">Figure 9</xref>. Its performance at predicting outcome variables at the 180-day follow-up visit (any computed tomography [CT] lung abnormalities, moderate-to-severe lung CT abnormalities [severity score &gt; 5], functional lung impairment, and persistent symptoms) in the entire cohort, mild-to-moderate (outpatient or hospitalized without oxygen), and severe-to-critical COVID-19 convalescents (oxygen therapy or ICU) in repeated 20-fold cross-validation (five repeats) was assessed by receiver-operating characteristic (ROC) (<xref ref-type="table" rid="app1table6">Appendix 1—table 6</xref>). ROC curves and statistics (AUC: area under the curve; Se: sensitivity; Sp: specificity) in the cross-validation are shown. Numbers of complete observations and outcome events are indicated in the plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72500-fig10-v2.tif"/></fig><p>The most important explanatory variables for pulmonary abnormalities by three unrelated classifiers (C5.0, RF, and glmNet) included preexisting malignancy, multimorbidity, markers of systemic inflammation (IL-6 and CRP), and anti-S1/S2 antibody levels at the 60-day follow-up (<xref ref-type="fig" rid="fig9s4">Figure 9—figure supplement 4</xref>, <xref ref-type="fig" rid="fig9s5">Figure 9—figure supplement 5</xref>, <xref ref-type="fig" rid="fig9s6">Figure 9—figure supplement 6</xref>). The highly influential parameters at prediction of symptoms at the 180-day follow-up encompassed symptom presence at the 60-day follow-up, as well as obesity and dyspnea during acute COVID-19 (<xref ref-type="fig" rid="fig9s7">Figure 9—figure supplement 7</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Herein, we prospectively evaluated trajectories of COVID-19 recovery in an observational cohort enrolled in the Austrian CovILD study (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>)⁠. Despite the resolution of symptoms and pulmonary abnormalities at the 6-month follow-up in a large fraction of the study participants, the recovery pace was substantially slower in the late convalescence when compared with the first three months after diagnosis (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 2021a</xref>)⁠. Persistent symptoms and CT findings were detected in more than 40% and reduced LF in approximately one-third of the cohort, which is in line with recovery kinetics and signs of lung lesion chronicity reported by others (<xref ref-type="bibr" rid="bib7">Caruso et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib15">Faverio et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Hellemons et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Zhou et al., 2021</xref>)⁠. By comparison, similar protracted pulmonary recovery was reported for SARS (<xref ref-type="bibr" rid="bib24">Hui et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Ng et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Ngai et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Lam et al., 2009</xref>)⁠ and non-COVID-19 acute respiratory distress syndrome (<xref ref-type="bibr" rid="bib57">Wilcox et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Masclans et al., 2011</xref>)⁠. Of note, treatment approaches for hospitalized patients in our cohorts and similar cohorts recruited at the pandemic onset in early 2020 (<xref ref-type="bibr" rid="bib7">Caruso et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib15">Faverio et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Hellemons et al., 2021</xref>)⁠ differ significantly from the current standard of care for acute COVID-19, which includes early systemic steroid use and antiviral and various immunomodulatory medications. How improved standardized therapy and anti-SARS-CoV-2 vaccination affect the clinical and pulmonary recovery needs to be investigated.</p><p>In roughly half of our study participants with abnormal lung CT findings, and especially in those with low-grade structural abnormalities, no overt LF impairment at follow-up was discerned. Still, even subclinical lung alterations may bear the potential for clinically relevant progression of interstitial lung disease (<xref ref-type="bibr" rid="bib48">Suliman et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Hatabu et al., 2020</xref>) requiring systematic CT and LF monitoring. Conversely, symptom persistence was weakly associated with incomplete functional or structural pulmonary recovery.</p><p>Since PASC are found in as many as 10% of COVID-19 patients (<xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Venkatesan, 2021</xref>; <xref ref-type="bibr" rid="bib47">Sudre et al., 2021b</xref>)⁠, robust, resource-saving tools assessing the individual risk of pulmonary complications are urgently needed (<xref ref-type="bibr" rid="bib43">Shah et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Raghu and Wilson, 2020</xref>)⁠. Covariates and characteristics of severe acute COVID-19 such as male sex, age, and preexisting comorbidities, hospitalization, ventilation, and ICU stay were proposed as the risk factors of persistent pulmonary impairment (<xref ref-type="bibr" rid="bib45">Sonnweber et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Caruso et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib15">Faverio et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Raghu and Wilson, 2020</xref>)⁠. However, their applicability in predicting complications of pulmonary recovery from mild or moderate COVID-19 is limited. Our results of univariate modeling, clustering, and ML prediction point towards a distinct long-term pulmonary risk phenotype that manifests during acute COVID-19 and early recovery and whose central components are protracted systemic (IL-6, CRP, anemia of inflammation) and microvascular inflammation (D-dimer), and strong humoral response (anti-S1/S2 IgG) demographic risk factors and comorbidities (<xref ref-type="bibr" rid="bib44">Sonnweber et al., 2020</xref>)⁠. Hence, consecutive monitoring of systemic inflammatory parameters analogous to concepts of interstitial lung disease in autoimmune disorders (<xref ref-type="bibr" rid="bib26">Khanna et al., 2020</xref>) and anti-S1/S2 antibody levels may improve identification of the individuals at risk of chronic pulmonary damage irrespective of the acute COVID-19 severity.</p><p>Clustering and ML have been employed for deep phenotyping and predicting acute and post-acute COVID-19 outcomes in multivariable data sets (<xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Sudre et al., 2021a</xref>; <xref ref-type="bibr" rid="bib13">Estiri et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Demichev et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Benito-León et al., 2021</xref>)⁠. We demonstrate that subsets of COVID-19 patients that significantly differ in the risk for long-term CT abnormalities may be defined by an easily accessible clinical parameter set available at the early post-COVID-19 assessment. This approach did not involve any CT or LF variables. Furthermore, the cluster classification correlated with the risk of long-term pulmonary abnormalities independently of the acute COVID-19 severity. Thus, these characteristics provide a useful tool for broad screening of convalescent populations, including individuals who experienced mild or moderate COVID-19.</p><p>We show that technically unrelated ML classifiers and their ensemble trained without CT and LF explanatory variables can predict lung CT findings independently of their grading at the 6-month follow-up with good specificity and sensitivity in the training collective and CV. By contrast, the more specific prediction of moderate-to-severe lung CT or risk estimation for LF deficits demonstrated a limited sensitivity. For the moderate-to-severe CT abnormalities, this can be primarily traced back to their low frequency resulting in a suboptimal classifier training, especially in CV. A substantial fraction of the participants (20.7%, n = 30) suffered from a preexisting respiratory condition (pulmonary disease, asthma, or COPD) likely paralleled by LF reduction, which possibly confounded the prediction of the post-COVID-19 LF deficits both by clustering and ML. Accumulating evidence suggests that post-acute COVID-19 symptoms are highly heterogeneous conditions with multiorgan, neurocognitive, and psychological manifestations (<xref ref-type="bibr" rid="bib42">Sahanic et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Evans et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Davis et al., 2021</xref>)⁠, which may differ in risk factor constellations. This could explain why univariate modeling, clustering, and ML failed to estimate persistent symptom risk in our small study cohort. In general, the ML prediction quality may greatly benefit from a larger training data set and inclusion of additional explanatory variables such as cellular readouts of inflammation, in-depth medication, and broader acute symptom data. Nevertheless, the herein described cluster- and ML classifiers represent resource-effective tools that may assist in the screening of medical record data and identification of COVID-19 patients requiring systematic CT and LF monitoring. To facilitate the identification of patients at risk for protracted respiratory recovery and enable validation in an external collective, we implemented the clustering and prediction procedures in an open-source risk assessment application (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>).</p><p>Our study bears limitations primarily concerning the low sample size and the cross-sectional character of the trial. Because of the impaired availability of the patients and the prolonged inpatient rehabiliation, the 60- and 100-day follow-up visits in part showed a temporal overlap that may have impacted the accuracy of the longitudinal data. Missingness of the consecutive outcome variable record and the participant dropout, particularly of mild and moderate COVID-19 cases, may have also potentially confounded the participant clustering results and ML risk estimation for CT abnormalities and LF impairment since prolonged hospitalization was found to be a crucial cluster-defining and influential explanatory feature. Additionally, even though the reproducibility of the risk assessment algorithms was partially addressed by CV, cluster and ML classifiers call for verification in a larger, independent multicenter collective of COVID-19 convalescents.</p><p>In summary, in our CovILD study cohort we found a high frequency of CT and LF abnormalities and persistent symptoms at the 6-month follow-up, and a flattened recovery kinetics after 3 months post-COVID-19. Systematic risk modeling reveled a set of clinical variables linked to protracted pulmonary recovery apart from the severity of acute infection such as inflammatory markers, anti-S1/S2 IgG levels, multimorbidity, and male sex. We demonstrate that clustering and ML classifiers may help to identify individuals at risk of persistent lung lesions and to relocate medical resources to prevent long-term disability.</p></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>owns his own business, Data Analytics as a Service Tirol, for which he performs freelance data science work. Has also received an honorarium for the study data management, curation and analysis and minor manuscript work. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Investigation, Methodology, Project administration, Resources</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Project administration, Resources</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Project administration, Resources</p></fn><fn fn-type="con" id="con9"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con15"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con16"><p>Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Investigation, Methodology, Project administration, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Investigation, Methodology, Project administration, Resources</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All participants gave written informed consent. The study was approved by the institutional review board at the Medical University of Innsbruck (approval number: 1103/2020), and registered at ClinicalTrials.gov (NCT04416100).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-72500-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Figure plots source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72500-data1-v2.xlsx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The complete R analysis pipeline and the anonymized study data in form of stratified study variables are available as a public GitHub repository: <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/CovILD_6_Months">https://github.com/PiotrTymoszuk/CovILD_6_Months</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:70dd08a32ded6d7fd23ec9c3c3cdbbaa567efb09;origin=https://github.com/PiotrTymoszuk/CovILD_6_Months;visit=swh:1:snp:5a2a66339f01f0eae69e4e3ee3a570d740b446a7;anchor=swh:1:rev:df521ede1d284e074a0484d3e4d0ce71097d00c3">swh:1:rev:df521ede1d284e074a0484d3e4d0ce71097d00c3</ext-link>). The R code for the key tools used for uni-variate modeling and model quality control (Figures 4 and 5, <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/lmqc">https://github.com/PiotrTymoszuk/lmqc</ext-link>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e8fe13a15a76dac675509c0da4d1a0f5099d7663;origin=https://github.com/PiotrTymoszuk/lmqc;visit=swh:1:snp:9f71c8c9aa0e5a19dab1a93f56dbc448d7c9a75e;anchor=swh:1:rev:a020119d8f23b60901115c5c2ce6f6c71998ed31">swh:1:rev:a020119d8f23b60901115c5c2ce6f6c71998ed31</ext-link>), cluster analysis and its quality control (Figures 6–7, <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/clustering-tools-2">https://github.com/PiotrTymoszuk/clustering-tools-2</ext-link>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:6fe3f573f9d178d0c705ee961e8d0df62a045d64;origin=https://github.com/PiotrTymoszuk/clustering-tools-2;visit=swh:1:snp:89046338e30935a0901e910b882909627c95ce16;anchor=swh:1:rev:64141197ca28838a8978dce9093443537157d79f">swh:1:rev:64141197ca28838a8978dce9093443537157d79f</ext-link>) and the risk assessment applicaiton (<ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app">https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app</ext-link>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:1408e446412645905e143dab84dab343fdf59b46;origin=https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app;visit=swh:1:snp:5a43a1401f424f76c9c3131dbb2a4f3cf880c966;anchor=swh:1:rev:95f02215f4c13425d3b76f6a13b7862a53279ab9">swh:1:rev:95f02215f4c13425d3b76f6a13b7862a53279ab9</ext-link>) is available at GitHub. Source data for Figures 2–10 has been included as Source data 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge the commitment of the staff and providers of our institutions through the COVID-19 crisis and the suffering and loss of our patients as well as their families. PT is (from May 2021 on) a freelance data scientist working in his own enterprise ‘Data Analytics as a Service Tirol’. He received an honorary for the study data management, curation and analysis and minor manuscript work. The other authors declare no conflict of interest related to this study. The study was funded by the research fund of the state of Tyrol (Project GZ 71934, JLR) and an Investigator-Initiated Study grant by Boehringer Ingelheim (IIS 1199-0424, IT). The funding bodies did not influence the development of the research and manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>G</given-names></name><name><surname>Gennaro</surname><given-names>C</given-names></name><name><surname>Oria</surname><given-names>V</given-names></name><name><surname>Radovanović</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><chapter-title>Similarity Search and Applications</chapter-title><source>Faster K-Medoids Clustering: Improving the PAM, CLARA, and CLARANS</source><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><fpage>171</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-32047-8</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Mächler</surname><given-names>M</given-names></name><name><surname>Bolker</surname><given-names>BM</given-names></name><name><surname>Walker</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fitting linear mixed-effects models using lme4</article-title><source>Journal of Statistical Software</source><volume>67</volume><fpage>1</fpage><lpage>48</lpage></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benito-León</surname><given-names>J</given-names></name><name><surname>Del Castillo</surname><given-names>MD</given-names></name><name><surname>Estirado</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Dubey</surname><given-names>S</given-names></name><name><surname>Serrano</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Using Unsupervised Machine Learning to Identify Age- and Sex-Independent Severity Subgroups Among Patients with COVID-19: Observational Longitudinal Study</article-title><source>Journal of Medical Internet Research</source><volume>23</volume><elocation-id>e25988</elocation-id><pub-id pub-id-type="doi">10.2196/25988</pub-id><pub-id pub-id-type="pmid">33872186</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Boriah</surname><given-names>S</given-names></name><name><surname>Chandola</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><conf-name>Similarity Measures for Categorical Data: A Comparative Evaluation</conf-name><article-title>Proceedings of the 2008 SIAM International Conference on Data Mining</article-title><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1137/1.9781611972788.22</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breiman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Random forests</article-title><source>Machine Learning</source><volume>45</volume><fpage>5</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1023/A:1010933404324</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>D</given-names></name><name><surname>Guido</surname><given-names>G</given-names></name><name><surname>Zerunian</surname><given-names>M</given-names></name><name><surname>Polidori</surname><given-names>T</given-names></name><name><surname>Lucertini</surname><given-names>E</given-names></name><name><surname>Pucciarelli</surname><given-names>F</given-names></name><name><surname>Polici</surname><given-names>M</given-names></name><name><surname>Rucci</surname><given-names>C</given-names></name><name><surname>Bracci</surname><given-names>B</given-names></name><name><surname>Nicolai</surname><given-names>M</given-names></name><name><surname>Cremona</surname><given-names>A</given-names></name><name><surname>De Dominicis</surname><given-names>C</given-names></name><name><surname>Laghi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up</article-title><source>Radiology</source><volume>301</volume><fpage>E396</fpage><lpage>E405</lpage><pub-id pub-id-type="doi">10.1148/radiol.2021210834</pub-id><pub-id pub-id-type="pmid">34313468</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croux</surname><given-names>C</given-names></name><name><surname>Filzmoser</surname><given-names>P</given-names></name><name><surname>Oliveira</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Algorithms for Projection–Pursuit robust principal component analysis</article-title><source>Chemometrics and Intelligent Laboratory Systems</source><volume>87</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.chemolab.2007.01.004</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>HE</given-names></name><name><surname>Assaf</surname><given-names>GS</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Low</surname><given-names>RJ</given-names></name><name><surname>Re’em</surname><given-names>Y</given-names></name><name><surname>Redfield</surname><given-names>S</given-names></name><name><surname>Austin</surname><given-names>JP</given-names></name><name><surname>Akrami</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterizing long COVID in an international cohort: 7 months of symptoms and their impact</article-title><source>EClinicalMedicine</source><volume>38</volume><elocation-id>101019</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101019</pub-id><pub-id pub-id-type="pmid">34308300</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Deane-Mayer</surname><given-names>ZA</given-names></name><name><surname>Knowles</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>R Package Caret</data-title><source>Ensemble Version 2.0.1</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=caretEnsemble">https://cran.r-project.org/package=caretEnsemble</ext-link></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demichev</surname><given-names>V</given-names></name><name><surname>Tober-Lau</surname><given-names>P</given-names></name><name><surname>Lemke</surname><given-names>O</given-names></name><name><surname>Nazarenko</surname><given-names>T</given-names></name><name><surname>Thibeault</surname><given-names>C</given-names></name><name><surname>Whitwell</surname><given-names>H</given-names></name><name><surname>Röhl</surname><given-names>A</given-names></name><name><surname>Freiwald</surname><given-names>A</given-names></name><name><surname>Szyrwiel</surname><given-names>L</given-names></name><name><surname>Ludwig</surname><given-names>D</given-names></name><name><surname>Correia-Melo</surname><given-names>C</given-names></name><name><surname>Aulakh</surname><given-names>SK</given-names></name><name><surname>Helbig</surname><given-names>ET</given-names></name><name><surname>Stubbemann</surname><given-names>P</given-names></name><name><surname>Lippert</surname><given-names>LJ</given-names></name><name><surname>Grüning</surname><given-names>N-M</given-names></name><name><surname>Blyuss</surname><given-names>O</given-names></name><name><surname>Vernardis</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>M</given-names></name><name><surname>Messner</surname><given-names>CB</given-names></name><name><surname>Joannidis</surname><given-names>M</given-names></name><name><surname>Sonnweber</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>SJ</given-names></name><name><surname>Pizzini</surname><given-names>A</given-names></name><name><surname>Wohlfarter</surname><given-names>Y</given-names></name><name><surname>Sahanic</surname><given-names>S</given-names></name><name><surname>Hilbe</surname><given-names>R</given-names></name><name><surname>Schaefer</surname><given-names>B</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Mittermaier</surname><given-names>M</given-names></name><name><surname>Machleidt</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Ruwwe-Glösenkamp</surname><given-names>C</given-names></name><name><surname>Lingscheid</surname><given-names>T</given-names></name><name><surname>Bosquillon de Jarcy</surname><given-names>L</given-names></name><name><surname>Stegemann</surname><given-names>MS</given-names></name><name><surname>Pfeiffer</surname><given-names>M</given-names></name><name><surname>Jürgens</surname><given-names>L</given-names></name><name><surname>Denker</surname><given-names>S</given-names></name><name><surname>Zickler</surname><given-names>D</given-names></name><name><surname>Enghard</surname><given-names>P</given-names></name><name><surname>Zelezniak</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Porteous</surname><given-names>DJ</given-names></name><name><surname>Marioni</surname><given-names>RE</given-names></name><name><surname>Uhrig</surname><given-names>A</given-names></name><name><surname>Müller-Redetzky</surname><given-names>H</given-names></name><name><surname>Zoller</surname><given-names>H</given-names></name><name><surname>Löffler-Ragg</surname><given-names>J</given-names></name><name><surname>Keller</surname><given-names>MA</given-names></name><name><surname>Tancevski</surname><given-names>I</given-names></name><name><surname>Timms</surname><given-names>JF</given-names></name><name><surname>Zaikin</surname><given-names>A</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Ramharter</surname><given-names>M</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>Lilley</surname><given-names>K</given-names></name><name><surname>Mülleder</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><collab>PA-COVID-19 Study group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>A time-resolved proteomic and prognostic map of COVID-19</article-title><source>Cell Systems</source><volume>12</volume><fpage>780</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2021.05.005</pub-id><pub-id pub-id-type="pmid">34139154</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Gardner</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>The Lancet. Infectious Diseases</source><volume>20</volume><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id><pub-id pub-id-type="pmid">32087114</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estiri</surname><given-names>H</given-names></name><name><surname>Strasser</surname><given-names>ZH</given-names></name><name><surname>Brat</surname><given-names>GA</given-names></name><name><surname>Semenov</surname><given-names>YR</given-names></name><name><surname>Patel</surname><given-names>CJ</given-names></name><name><surname>Murphy</surname><given-names>SN</given-names></name><collab>Consortium for Characterization of COVID-19 by EHR (4CE)</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Evolving phenotypes of non-hospitalized patients that indicate long COVID</article-title><source>BMC Medicine</source><volume>19</volume><elocation-id>249</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-021-02115-0</pub-id><pub-id pub-id-type="pmid">34565368</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RA</given-names></name><name><surname>McAuley</surname><given-names>H</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Shikotra</surname><given-names>A</given-names></name><name><surname>Singapuri</surname><given-names>A</given-names></name><name><surname>Sereno</surname><given-names>M</given-names></name><name><surname>Elneima</surname><given-names>O</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>Lone</surname><given-names>NI</given-names></name><name><surname>Leavy</surname><given-names>OC</given-names></name><name><surname>Daines</surname><given-names>L</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Chalder</surname><given-names>T</given-names></name><name><surname>De Soyza</surname><given-names>A</given-names></name><name><surname>Diar Bakerly</surname><given-names>N</given-names></name><name><surname>Easom</surname><given-names>N</given-names></name><name><surname>Geddes</surname><given-names>JR</given-names></name><name><surname>Greening</surname><given-names>NJ</given-names></name><name><surname>Hart</surname><given-names>N</given-names></name><name><surname>Heaney</surname><given-names>LG</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>L</given-names></name><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Jacob</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>RG</given-names></name><name><surname>Jolley</surname><given-names>C</given-names></name><name><surname>Kerr</surname><given-names>S</given-names></name><name><surname>Kon</surname><given-names>OM</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Lord</surname><given-names>JM</given-names></name><name><surname>McCann</surname><given-names>GP</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Pfeffer</surname><given-names>P</given-names></name><name><surname>Rahman</surname><given-names>NM</given-names></name><name><surname>Raman</surname><given-names>B</given-names></name><name><surname>Richardson</surname><given-names>M</given-names></name><name><surname>Rowland</surname><given-names>M</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name><name><surname>Singh</surname><given-names>SJ</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Toshner</surname><given-names>M</given-names></name><name><surname>Chalmers</surname><given-names>JD</given-names></name><name><surname>Ho</surname><given-names>LP</given-names></name><name><surname>Horsley</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>M</given-names></name><name><surname>Poinasamy</surname><given-names>K</given-names></name><name><surname>Wain</surname><given-names>LV</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><collab>PHOSP-COVID Collaborative Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study</article-title><source>The Lancet. Respiratory Medicine</source><volume>9</volume><fpage>1275</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00383-0</pub-id><pub-id pub-id-type="pmid">34627560</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faverio</surname><given-names>P</given-names></name><name><surname>Luppi</surname><given-names>F</given-names></name><name><surname>Rebora</surname><given-names>P</given-names></name><name><surname>Busnelli</surname><given-names>S</given-names></name><name><surname>Stainer</surname><given-names>A</given-names></name><name><surname>Catalano</surname><given-names>M</given-names></name><name><surname>Parachini</surname><given-names>L</given-names></name><name><surname>Monzani</surname><given-names>A</given-names></name><name><surname>Galimberti</surname><given-names>S</given-names></name><name><surname>Bini</surname><given-names>F</given-names></name><name><surname>Bodini</surname><given-names>BD</given-names></name><name><surname>Betti</surname><given-names>M</given-names></name><name><surname>De Giacomi</surname><given-names>F</given-names></name><name><surname>Scarpazza</surname><given-names>P</given-names></name><name><surname>Oggionni</surname><given-names>E</given-names></name><name><surname>Scartabellati</surname><given-names>A</given-names></name><name><surname>Bilucaglia</surname><given-names>L</given-names></name><name><surname>Ceruti</surname><given-names>P</given-names></name><name><surname>Modina</surname><given-names>D</given-names></name><name><surname>Harari</surname><given-names>S</given-names></name><name><surname>Caminati</surname><given-names>A</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name><name><surname>Bellani</surname><given-names>G</given-names></name><name><surname>Foti</surname><given-names>G</given-names></name><name><surname>Pesci</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study</article-title><source>Respiration; International Review of Thoracic Diseases</source><volume>100</volume><fpage>1078</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1159/000518141</pub-id><pub-id pub-id-type="pmid">34515212</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D</given-names></name><name><surname>Clementi</surname><given-names>N</given-names></name><name><surname>Spanò</surname><given-names>SM</given-names></name><name><surname>Albitar-Nehme</surname><given-names>S</given-names></name><name><surname>Ranno</surname><given-names>S</given-names></name><name><surname>Colombini</surname><given-names>A</given-names></name><name><surname>Criscuolo</surname><given-names>E</given-names></name><name><surname>Di Resta</surname><given-names>C</given-names></name><name><surname>Tomaiuolo</surname><given-names>R</given-names></name><name><surname>Viganó</surname><given-names>M</given-names></name><name><surname>Mancini</surname><given-names>N</given-names></name><name><surname>De Vecchi</surname><given-names>E</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Perno</surname><given-names>CF</given-names></name><name><surname>Banfi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>522</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2021.08.024</pub-id><pub-id pub-id-type="pmid">34425105</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleiss</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Everitt</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Large sample standard errors of kappa and weighted kappa</article-title><source>Psychological Bulletin</source><volume>72</volume><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1037/h0028106</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regularization Paths for Generalized Linear Models via Coordinate Descent</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.18637/jss.v033.i01</pub-id><pub-id pub-id-type="pmid">20808728</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatabu</surname><given-names>H</given-names></name><name><surname>Hunninghake</surname><given-names>GM</given-names></name><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Wells</surname><given-names>AU</given-names></name><name><surname>Remy-Jardin</surname><given-names>M</given-names></name><name><surname>Verschakelen</surname><given-names>J</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Beasley</surname><given-names>MB</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>San José Estépar</surname><given-names>R</given-names></name><name><surname>Seo</surname><given-names>JB</given-names></name><name><surname>Johkoh</surname><given-names>T</given-names></name><name><surname>Sverzellati</surname><given-names>N</given-names></name><name><surname>Ryerson</surname><given-names>CJ</given-names></name><name><surname>Graham Barr</surname><given-names>R</given-names></name><name><surname>Goo</surname><given-names>JM</given-names></name><name><surname>Austin</surname><given-names>JHM</given-names></name><name><surname>Powell</surname><given-names>CA</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Lynch</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>726</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30168-5</pub-id><pub-id pub-id-type="pmid">32649920</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellemons</surname><given-names>ME</given-names></name><name><surname>Huijts</surname><given-names>S</given-names></name><name><surname>Bek</surname><given-names>L</given-names></name><name><surname>Berentschot</surname><given-names>J</given-names></name><name><surname>Nakshbandi</surname><given-names>G</given-names></name><name><surname>Schurink</surname><given-names>CAM</given-names></name><name><surname>Vlake</surname><given-names>J</given-names></name><name><surname>van Genderen</surname><given-names>ME</given-names></name><name><surname>van Bommel</surname><given-names>J</given-names></name><name><surname>Gommers</surname><given-names>D</given-names></name><name><surname>Odink</surname><given-names>A</given-names></name><name><surname>Ciet</surname><given-names>P</given-names></name><name><surname>Shamier</surname><given-names>MC</given-names></name><name><surname>GeurtsvanKessel</surname><given-names>C</given-names></name><name><surname>Baart</surname><given-names>SJ</given-names></name><name><surname>Ribbers</surname><given-names>GM</given-names></name><name><surname>van den Berg-Emons</surname><given-names>HG</given-names></name><name><surname>Heijenbrok-Kal</surname><given-names>MH</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for SARS-CoV-2; A Longitudinal Study of Respiratory, Physical and Psychological Outcomes</article-title><source>Annals of the American Thoracic Society</source><volume>10</volume><elocation-id>340OC</elocation-id><pub-id pub-id-type="doi">10.1513/AnnalsATS.202103-340OC</pub-id><pub-id pub-id-type="pmid">34582728</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study</article-title><source>Lancet (London, England)</source><volume>397</volume><fpage>220</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32656-8</pub-id><pub-id pub-id-type="pmid">33428867</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study</article-title><source>Lancet (London, England)</source><volume>398</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01755-4</pub-id><pub-id pub-id-type="pmid">34454673</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Tam</surname><given-names>LS</given-names></name><name><surname>Chan</surname><given-names>DP</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors</article-title><source>Chest</source><volume>128</volume><fpage>2247</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1378/chest.128.4.2247</pub-id><pub-id pub-id-type="pmid">16236881</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Johns Hopkins Coronavirus Resource Center</collab></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 Map</article-title><ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link><date-in-citation iso-8601-date="2021-05-20">May 20, 2021</date-in-citation></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>D</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Denton</surname><given-names>CP</given-names></name><name><surname>Renzoni</surname><given-names>EA</given-names></name><name><surname>Desai</surname><given-names>SR</given-names></name><name><surname>Varga</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>201</volume><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1164/rccm.201903-0563CI</pub-id><pub-id pub-id-type="pmid">31841044</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kohonen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><source>Self-Organizing Maps</source><publisher-loc>Berlin, Heidelberg</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-642-97610-0</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Building predictive models in R using the caret package</article-title><source>Journal of Statistical Software</source><volume>28</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.18637/jss.v028.i05</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsova</surname><given-names>A</given-names></name><name><surname>Brockhoff</surname><given-names>PB</given-names></name><name><surname>Christensen</surname><given-names>RHB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>lmerTest Package: Tests in Linear Mixed Effects Models</article-title><source>Journal of Statistical Software</source><volume>82</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.18637/jss.v082.i13</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>MHB</given-names></name><name><surname>Wing</surname><given-names>YK</given-names></name><name><surname>Yu</surname><given-names>MWM</given-names></name><name><surname>Leung</surname><given-names>CM</given-names></name><name><surname>Ma</surname><given-names>RCW</given-names></name><name><surname>Kong</surname><given-names>APS</given-names></name><name><surname>So</surname><given-names>WY</given-names></name><name><surname>Fong</surname><given-names>SYY</given-names></name><name><surname>Lam</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up</article-title><source>Archives of Internal Medicine</source><volume>169</volume><fpage>2142</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2009.384</pub-id><pub-id pub-id-type="pmid">20008700</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>V</given-names></name><name><surname>Braun</surname><given-names>ML</given-names></name><name><surname>Buhmann</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Stability-based validation of clustering solutions</article-title><source>Neural Computation</source><volume>16</volume><fpage>1299</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1162/089976604773717621</pub-id><pub-id pub-id-type="pmid">15130251</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adaptive Semi-Supervised Clustering Algorithm with Label Propagation</article-title><source>Journal of Software Engineering</source><volume>8</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3923/jse.2014.14.22</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masclans</surname><given-names>JR</given-names></name><name><surname>Roca</surname><given-names>O</given-names></name><name><surname>Muñoz</surname><given-names>X</given-names></name><name><surname>Pallisa</surname><given-names>E</given-names></name><name><surname>Torres</surname><given-names>F</given-names></name><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Morell</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quality of life, pulmonary function, and tomographic scan abnormalities after ARDS</article-title><source>Chest</source><volume>139</volume><fpage>1340</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1378/chest.10-2438</pub-id><pub-id pub-id-type="pmid">21330382</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>Chan</surname><given-names>JWM</given-names></name><name><surname>Kwan</surname><given-names>TL</given-names></name><name><surname>To</surname><given-names>TS</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Ng</surname><given-names>FYY</given-names></name><name><surname>Mok</surname><given-names>TYW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors</article-title><source>Thorax</source><volume>59</volume><fpage>889</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1136/thx.2004.023762</pub-id><pub-id pub-id-type="pmid">15454656</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngai</surname><given-names>JC</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>To</surname><given-names>KW</given-names></name><name><surname>Tong</surname><given-names>M</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status</article-title><source>Respirology (Carlton, Vic.)</source><volume>15</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2010.01720.x</pub-id><pub-id pub-id-type="pmid">20337995</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Saez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland</article-title><source>The Lancet. Infectious Diseases</source><volume>21</volume><fpage>e69</fpage><lpage>e70</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30584-3</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Silva</surname><given-names>JG</given-names></name><name><surname>Araujo-Voces</surname><given-names>M</given-names></name><name><surname>Quesada</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>nVenn: generalized, quasi-proportional Venn and Euler diagrams</article-title><source>Bioinformatics (Oxford, England)</source><volume>34</volume><fpage>2322</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty109</pub-id><pub-id pub-id-type="pmid">29949954</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1993">1993</year><source>C4.5: Programs for Machine Learning</source><publisher-loc>San Francisco, CA, USA</publisher-loc><publisher-name>Morgan Kaufmann Publishers Inc</publisher-name></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 interstitial pneumonia: monitoring the clinical course in survivors</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>839</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30349-0</pub-id><pub-id pub-id-type="pmid">32758440</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ripley</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>Pattern Recognition and Neural Networks</source><publisher-loc>Cambridge</publisher-loc><publisher-name>Cambridge University Press</publisher-name><pub-id pub-id-type="doi">10.1017/CBO9780511812651</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>plotROC: A Tool for Plotting ROC Curves</article-title><source>Journal of Statistical Software</source><volume>79</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.18637/jss.v079.c02</pub-id><pub-id pub-id-type="pmid">30686944</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahanic</surname><given-names>S</given-names></name><name><surname>Tymoszuk</surname><given-names>P</given-names></name><name><surname>Ausserhofer</surname><given-names>D</given-names></name><name><surname>Rass</surname><given-names>V</given-names></name><name><surname>Pizzini</surname><given-names>A</given-names></name><name><surname>Nordmeyer</surname><given-names>G</given-names></name><name><surname>Hüfner</surname><given-names>K</given-names></name><name><surname>Kurz</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>PM</given-names></name><name><surname>Sonnweber</surname><given-names>T</given-names></name><name><surname>Boehm</surname><given-names>A</given-names></name><name><surname>Aichner</surname><given-names>M</given-names></name><name><surname>Cima</surname><given-names>K</given-names></name><name><surname>Boeckle</surname><given-names>B</given-names></name><name><surname>Holzner</surname><given-names>B</given-names></name><name><surname>Rumpold</surname><given-names>G</given-names></name><name><surname>Puelacher</surname><given-names>C</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>A</given-names></name><name><surname>Wiedermann</surname><given-names>CJ</given-names></name><name><surname>Sperner-Unterweger</surname><given-names>B</given-names></name><name><surname>Tancevski</surname><given-names>I</given-names></name><name><surname>Bellmann-Weiler</surname><given-names>R</given-names></name><name><surname>Bachler</surname><given-names>H</given-names></name><name><surname>Piccoliori</surname><given-names>G</given-names></name><name><surname>Helbok</surname><given-names>R</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Loeffler-Ragg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Phenotyping of acute and persistent COVID-19 features in the outpatient setting: exploratory analysis of an international cross-sectional online survey</article-title><source>Clinical Infectious Diseases</source><volume>2</volume><elocation-id>ciab978</elocation-id><pub-id pub-id-type="doi">10.1093/cid/ciab978</pub-id><pub-id pub-id-type="pmid">34849652</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>W</given-names></name><name><surname>Hillman</surname><given-names>T</given-names></name><name><surname>Playford</surname><given-names>ED</given-names></name><name><surname>Hishmeh</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline</article-title><source>BMJ (Clinical Research Ed.)</source><volume>372</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.n136</pub-id><pub-id pub-id-type="pmid">33483331</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnweber</surname><given-names>T</given-names></name><name><surname>Boehm</surname><given-names>A</given-names></name><name><surname>Sahanic</surname><given-names>S</given-names></name><name><surname>Pizzini</surname><given-names>A</given-names></name><name><surname>Aichner</surname><given-names>M</given-names></name><name><surname>Sonnweber</surname><given-names>B</given-names></name><name><surname>Kurz</surname><given-names>K</given-names></name><name><surname>Koppelstätter</surname><given-names>S</given-names></name><name><surname>Haschka</surname><given-names>D</given-names></name><name><surname>Petzer</surname><given-names>V</given-names></name><name><surname>Hilbe</surname><given-names>R</given-names></name><name><surname>Theurl</surname><given-names>M</given-names></name><name><surname>Lehner</surname><given-names>D</given-names></name><name><surname>Nairz</surname><given-names>M</given-names></name><name><surname>Puchner</surname><given-names>B</given-names></name><name><surname>Luger</surname><given-names>A</given-names></name><name><surname>Schwabl</surname><given-names>C</given-names></name><name><surname>Bellmann-Weiler</surname><given-names>R</given-names></name><name><surname>Wöll</surname><given-names>E</given-names></name><name><surname>Widmann</surname><given-names>G</given-names></name><name><surname>Tancevski</surname><given-names>I</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study</article-title><source>Respiratory Research</source><volume>21</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-020-01546-2</pub-id><pub-id pub-id-type="pmid">33087116</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnweber</surname><given-names>T</given-names></name><name><surname>Sahanic</surname><given-names>S</given-names></name><name><surname>Pizzini</surname><given-names>A</given-names></name><name><surname>Luger</surname><given-names>A</given-names></name><name><surname>Schwabl</surname><given-names>C</given-names></name><name><surname>Sonnweber</surname><given-names>B</given-names></name><name><surname>Kurz</surname><given-names>K</given-names></name><name><surname>Koppelstätter</surname><given-names>S</given-names></name><name><surname>Haschka</surname><given-names>D</given-names></name><name><surname>Petzer</surname><given-names>V</given-names></name><name><surname>Boehm</surname><given-names>A</given-names></name><name><surname>Aichner</surname><given-names>M</given-names></name><name><surname>Tymoszuk</surname><given-names>P</given-names></name><name><surname>Lener</surname><given-names>D</given-names></name><name><surname>Theurl</surname><given-names>M</given-names></name><name><surname>Lorsbach-Köhler</surname><given-names>A</given-names></name><name><surname>Tancevski</surname><given-names>A</given-names></name><name><surname>Schapfl</surname><given-names>A</given-names></name><name><surname>Schaber</surname><given-names>M</given-names></name><name><surname>Hilbe</surname><given-names>R</given-names></name><name><surname>Nairz</surname><given-names>M</given-names></name><name><surname>Puchner</surname><given-names>B</given-names></name><name><surname>Hüttenberger</surname><given-names>D</given-names></name><name><surname>Tschurtschenthaler</surname><given-names>C</given-names></name><name><surname>Aßhoff</surname><given-names>M</given-names></name><name><surname>Peer</surname><given-names>A</given-names></name><name><surname>Hartig</surname><given-names>F</given-names></name><name><surname>Bellmann</surname><given-names>R</given-names></name><name><surname>Joannidis</surname><given-names>M</given-names></name><name><surname>Gollmann-Tepeköylü</surname><given-names>C</given-names></name><name><surname>Holfeld</surname><given-names>J</given-names></name><name><surname>Feuchtner</surname><given-names>G</given-names></name><name><surname>Egger</surname><given-names>A</given-names></name><name><surname>Hoermann</surname><given-names>G</given-names></name><name><surname>Schroll</surname><given-names>A</given-names></name><name><surname>Fritsche</surname><given-names>G</given-names></name><name><surname>Wildner</surname><given-names>S</given-names></name><name><surname>Bellmann-Weiler</surname><given-names>R</given-names></name><name><surname>Kirchmair</surname><given-names>R</given-names></name><name><surname>Helbok</surname><given-names>R</given-names></name><name><surname>Prosch</surname><given-names>H</given-names></name><name><surname>Rieder</surname><given-names>D</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Wöll</surname><given-names>E</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Widmann</surname><given-names>G</given-names></name><name><surname>Löffler-Ragg</surname><given-names>J</given-names></name><name><surname>Tancevski</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial</article-title><source>The European Respiratory Journal</source><volume>57</volume><elocation-id>2003481</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.03481-2020</pub-id><pub-id pub-id-type="pmid">33303539</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>KA</given-names></name><name><surname>Lochlainn</surname><given-names>MN</given-names></name><name><surname>Varsavsky</surname><given-names>T</given-names></name><name><surname>Murray</surname><given-names>B</given-names></name><name><surname>Graham</surname><given-names>MS</given-names></name><name><surname>Menni</surname><given-names>C</given-names></name><name><surname>Modat</surname><given-names>M</given-names></name><name><surname>Bowyer</surname><given-names>RCE</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Drew</surname><given-names>DA</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>CG</given-names></name><name><surname>Lo</surname><given-names>CH</given-names></name><name><surname>Ganesh</surname><given-names>S</given-names></name><name><surname>Buwe</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>JC</given-names></name><name><surname>du Cadet</surname><given-names>JL</given-names></name><name><surname>Visconti</surname><given-names>A</given-names></name><name><surname>Freidin</surname><given-names>MB</given-names></name><name><surname>El-Sayed Moustafa</surname><given-names>JS</given-names></name><name><surname>Falchi</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>R</given-names></name><name><surname>Gomez</surname><given-names>MF</given-names></name><name><surname>Fall</surname><given-names>T</given-names></name><name><surname>Cardoso</surname><given-names>MJ</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Franks</surname><given-names>PW</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Steves</surname><given-names>CJ</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app</article-title><source>Science Advances</source><volume>7</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abd4177</pub-id><pub-id pub-id-type="pmid">33741586</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Murray</surname><given-names>B</given-names></name><name><surname>Varsavsky</surname><given-names>T</given-names></name><name><surname>Graham</surname><given-names>MS</given-names></name><name><surname>Penfold</surname><given-names>RS</given-names></name><name><surname>Bowyer</surname><given-names>RC</given-names></name><name><surname>Pujol</surname><given-names>JC</given-names></name><name><surname>Klaser</surname><given-names>K</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Canas</surname><given-names>LS</given-names></name><name><surname>Molteni</surname><given-names>E</given-names></name><name><surname>Modat</surname><given-names>M</given-names></name><name><surname>Jorge Cardoso</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>A</given-names></name><name><surname>Ganesh</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Drew</surname><given-names>DA</given-names></name><name><surname>Astley</surname><given-names>CM</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Merino</surname><given-names>J</given-names></name><name><surname>Tsereteli</surname><given-names>N</given-names></name><name><surname>Fall</surname><given-names>T</given-names></name><name><surname>Gomez</surname><given-names>MF</given-names></name><name><surname>Duncan</surname><given-names>EL</given-names></name><name><surname>Menni</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>FMK</given-names></name><name><surname>Franks</surname><given-names>PW</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Steves</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Attributes and predictors of long COVID</article-title><source>Nature Medicine</source><volume>27</volume><fpage>626</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01292-y</pub-id><pub-id pub-id-type="pmid">33692530</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suliman</surname><given-names>YA</given-names></name><name><surname>Dobrota</surname><given-names>R</given-names></name><name><surname>Huscher</surname><given-names>D</given-names></name><name><surname>Nguyen-Kim</surname><given-names>TDL</given-names></name><name><surname>Maurer</surname><given-names>B</given-names></name><name><surname>Jordan</surname><given-names>S</given-names></name><name><surname>Speich</surname><given-names>R</given-names></name><name><surname>Frauenfelder</surname><given-names>T</given-names></name><name><surname>Distler</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease</article-title><source>Arthritis &amp; Rheumatology (Hoboken, N.J.)</source><volume>67</volume><fpage>3256</fpage><lpage>3261</lpage><pub-id pub-id-type="doi">10.1002/art.39405</pub-id><pub-id pub-id-type="pmid">26316389</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NICE guideline on long COVID</article-title><source>The Lancet. Respiratory Medicine</source><volume>9</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00031-X</pub-id><pub-id pub-id-type="pmid">33453162</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesanto</surname><given-names>J</given-names></name><name><surname>Alhoniemi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Clustering of the self-organizing map</article-title><source>IEEE Transactions on Neural Networks</source><volume>11</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1109/72.846731</pub-id><pub-id pub-id-type="pmid">18249787</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Consistent selection of the number of clusters via crossvalidation</article-title><source>Biometrika</source><volume>97</volume><fpage>893</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1093/biomet/asq061</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehrens</surname><given-names>R</given-names></name><name><surname>Kruisselbrink</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Flexible self-organizing maps in kohonen 3.0</article-title><source>Journal of Statistical Software</source><volume>87</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.18637/jss.v087.i07</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>J</given-names></name><name><surname>Watkins</surname><given-names>C</given-names></name></person-group><conf-name>Multi-Class Support Vector Machines</conf-name><article-title>Proceedings, European Symposium on Artificial Neural Networks</article-title><year iso-8601-date="1998">1998</year><ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/221997121_Multi-Class_Support_Vector_Machine">https://www.researchgate.net/publication/221997121_Multi-Class_Support_Vector_Machine</ext-link></element-citation></ref><ref id="bib54"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Coronavirus</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/coronavirus#tab=tab_3">https://www.who.int/health-topics/coronavirus#tab=tab_3</ext-link><date-in-citation iso-8601-date="2021-05-20">May 20, 2021</date-in-citation></element-citation></ref><ref id="bib55"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><publisher-loc>Cham</publisher-loc><publisher-name>Springer-Verlag</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Averick</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>McGowan</surname><given-names>L</given-names></name><name><surname>François</surname><given-names>R</given-names></name><name><surname>Grolemund</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Bache</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Ooms</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Seidel</surname><given-names>D</given-names></name><name><surname>Spinu</surname><given-names>V</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Vaughan</surname><given-names>D</given-names></name><name><surname>Wilke</surname><given-names>C</given-names></name><name><surname>Woo</surname><given-names>K</given-names></name><name><surname>Yutani</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Welcome to the Tidyverse</article-title><source>Journal of Open Source Software</source><volume>4</volume><elocation-id>1686</elocation-id><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>ME</given-names></name><name><surname>Patsios</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Kudlow</surname><given-names>P</given-names></name><name><surname>Paul</surname><given-names>N</given-names></name><name><surname>Tansey</surname><given-names>CM</given-names></name><name><surname>Chu</surname><given-names>L</given-names></name><name><surname>Matte</surname><given-names>A</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Herridge</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Radiologic outcomes at 5 years after severe ARDS</article-title><source>Chest</source><volume>143</volume><fpage>920</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1378/chest.12-0685</pub-id><pub-id pub-id-type="pmid">23187463</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilke</surname><given-names>CO</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Fundamentals of Data Visualization: A Primer on Making Informative and Compelling Figures</source><publisher-loc>Sebastopol</publisher-loc><publisher-name>O’Reilly Media</publisher-name></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Tao</surname><given-names>M</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Assessment of Sequelae of COVID-19 Nearly 1 Year After Diagnosis</article-title><source>Frontiers in Medicine</source><volume>8</volume><elocation-id>717194</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.717194</pub-id><pub-id pub-id-type="pmid">34888318</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Study variables.</title><p>Variable: variable name in the analysis pipeline; reference time point: study visit, the variable was recorded at; label: variable label in figures and tables.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">Reference time point</th><th align="left" valign="bottom">Label</th><th align="left" valign="bottom">Variable type</th><th align="left" valign="bottom">Stratification cutoff</th></tr></thead><tbody><tr><td align="left" valign="bottom">sex_male_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Male sex</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">obesity_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Obesity</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">BMI &gt; 30 kg/m<sup>2</sup></td></tr><tr><td align="left" valign="bottom">current_smoker_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Current smoker</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">smoking_ex_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Ex-smoker</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CVDis_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">CVD</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">hypertension_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Hypertension</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">PDis_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">PD</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">COPD_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">COPD</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">asthma_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Asthma</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">endocrine_metabolic_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Metabolic disorders</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">hypercholesterolemia_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Hypercholesterolemia</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">diabetes_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Diabetes</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CKDis_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">CKD</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">GITDis_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">GITD</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">malignancy_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Malignancy</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">immune_deficiency_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Immune deficiency</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">weight_change_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Weight loss, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">≥1 kg</td></tr><tr><td align="left" valign="bottom">dyspnoe_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Dyspnea, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">cough_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Cough, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">fever_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Fever, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">night_sweat_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Night sweat, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">pain_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Pain, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">GI_sympt_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">GI symptoms, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">anosmia_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Anosmia, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">ECOG_imp_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Impaired performance, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">ECOG ≥ 1</td></tr><tr><td align="left" valign="bottom">sleep_disorder_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Sleep disorders, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">treat_antiinfec_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Anti-infectives, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">treat_antiplat_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Antiplatelet, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">treat_anticoag_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Anticoagulatives, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">treat_immunosuppr_rec_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Immunosuppression, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">anemia_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Anemia, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">Male: Hb &lt; 14 g/dL; female: Hb &lt;12 g/dL</td></tr><tr><td align="left" valign="bottom">ferr_elv_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Elevated ferritin, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">Male: &gt; 300 ng/mL; female: &gt; 150 ng/mL</td></tr><tr><td align="left" valign="bottom">NTelv_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Elevated NTproBNP, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;125 pg/mL</td></tr><tr><td align="left" valign="bottom">Ddimerelv_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Elevated D-dimer, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;500 pg/mL FEU</td></tr><tr><td align="left" valign="bottom">CRP_elv_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Elevated CRP, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;0.5 mg/dL</td></tr><tr><td align="left" valign="bottom">IL6_elv_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Elevated IL-6, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;7 pg/mL</td></tr><tr><td align="left" valign="bottom">iron_deficiency_30_rec_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Iron deficiency, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">TF-saturation &lt; 15%</td></tr><tr><td align="left" valign="bottom">age_65_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Age over 65</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;65 years</td></tr><tr><td align="left" valign="bottom">hosp_7d_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Hospitalized &gt; 7 days, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;7 days</td></tr><tr><td align="left" valign="bottom">comorb_present_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Any comorbidity</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;0 comorbidities</td></tr><tr><td align="left" valign="bottom">comorb_3_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">&gt;3 comorbidities</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;3 comorbidities</td></tr><tr><td align="left" valign="bottom">overweight_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Overweight or obesity</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">BMI &gt; 25 kg/m<sup>2</sup></td></tr><tr><td align="left" valign="bottom">sympt_6_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">&gt;6 symptoms, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;6 symptoms</td></tr><tr><td align="left" valign="bottom">sympt_present_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Persistent symptoms, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt;0 symptoms at 180-day visit</td></tr><tr><td align="left" valign="bottom">ab_0_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q1, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">(0, 312] BAU/mL</td></tr><tr><td align="left" valign="bottom">ab_25_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q2, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">(312, 644] BAU/mL</td></tr><tr><td align="left" valign="bottom">ab_50_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q3, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">(644, 975] BAU/mL</td></tr><tr><td align="left" valign="bottom">ab_75_V1</td><td align="left" valign="bottom">60-day follow-up</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q4, 60-day visit</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom">&gt; 975 BAU/mL</td></tr><tr><td align="left" valign="bottom">pat_group_G1_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Ambulatory, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">pat_group_G2_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Hospitalized, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">pat_group_G3_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">Oxygen therapy, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">pat_group_G4_V0</td><td align="left" valign="bottom">Acute COVID-19</td><td align="left" valign="bottom">ICU, acute COVID-19</td><td align="left" valign="bottom">Explanatory</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CT_findings_V3</td><td align="left" valign="bottom">180-day follow-up</td><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Outcome</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CT_sev_low_V3</td><td align="left" valign="bottom">180-day follow-up</td><td align="left" valign="bottom">CT severity score 1–5 at 180-day visit</td><td align="left" valign="bottom">Outcome</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CTsevabove5_V3</td><td align="left" valign="bottom">180-day follow-up</td><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Outcome</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">sympt_present_V3</td><td align="left" valign="bottom">180-day follow-up</td><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Outcome</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">lung_function_impaired_V3</td><td align="left" valign="bottom">180-day follow-up</td><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Outcome</td><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>CVD = cardiovascular disease; PD = pulmonary disease; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; GITD = gastrointestinal disease; GI = gastrointestinal; CRP = C-reactive protein; ICU = intensive care unit; CT = computed tomography; BMI = body mass index; BAU = binding antibody unit.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Results of univariate risk modeling.</title><p>Outcome: outcome variable at the 180-day follow-up visit; covariate: explanatory variable; baseline: reference level of the explanatory variable; OR: odds ratios with 95% confidence intervals; pFDR: significanct p-value corrected for multiple testing with the Benjamini–Hochberg method (FDR: false discovery rate).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Outcome</th><th align="left" valign="bottom">Covariate</th><th align="left" valign="bottom">Baseline</th><th align="left" valign="bottom">Complete cases</th><th align="left" valign="bottom">OR</th><th align="left" valign="bottom">pFDR</th></tr></thead><tbody><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Male sex, n = 63</td><td align="left" valign="bottom">No male sex, n = 55</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.79 [1.77–8.44]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Obesity, n = 22</td><td align="left" valign="bottom">No obesity, n = 96</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.07 [0.415–2.72]</td><td align="left" valign="bottom">ns (p=0.9)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Current smoker, n = 4</td><td align="left" valign="bottom">No current smoker, n = 114</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.412 [0.02–3.33]</td><td align="left" valign="bottom">ns (p=0.51)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Ex-smoker, n = 48</td><td align="left" valign="bottom">No ex-smoker, n = 70</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.5 [0.716–3.16]</td><td align="left" valign="bottom">ns (p=0.36)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">CVD, n = 45</td><td align="left" valign="bottom">No CVD, n = 73</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.36 [1.57–7.43]</td><td align="left" valign="bottom">p=0.012</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Hypertension, n = 34</td><td align="left" valign="bottom">No hypertension, n = 84</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.97 [1.73–9.54]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">PD, n = 24</td><td align="left" valign="bottom">No PD, n = 94</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.06 [0.837–5.25]</td><td align="left" valign="bottom">ns (p=0.2)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">COPD, n = 6</td><td align="left" valign="bottom">No COPD, n = 112</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.67 [0.499–19.8]</td><td align="left" valign="bottom">ns (p=0.34)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Asthma, n = 9</td><td align="left" valign="bottom">No asthma, n = 109</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.02 [0.24–4.04]</td><td align="left" valign="bottom">ns (p=0.99)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Metabolic disorders, n = 50</td><td align="left" valign="bottom">No metabolic disorders, n = 68</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.14 [1.48–6.81]</td><td align="left" valign="bottom">p=0.017</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Hypercholesterolemia, n = 22</td><td align="left" valign="bottom">No hypercholesterolemia, n = 96</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.67 [1.04–7.27]</td><td align="left" valign="bottom">ns (p=0.093)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Diabetes, n = 18</td><td align="left" valign="bottom">No diabetes, n = 100</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.07 [1.41–13.5]</td><td align="left" valign="bottom">p=0.041</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">GITD, n = 17</td><td align="left" valign="bottom">No GITD, n = 101</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.66 [1.25–12.2]</td><td align="left" valign="bottom">ns (p=0.061)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Malignancy, n = 13</td><td align="left" valign="bottom">No malignancy, n = 105</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">19.5 [3.63–362]</td><td align="left" valign="bottom">p=0.021</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Immune deficiency, n = 5</td><td align="left" valign="bottom">No immune deficiency, n = 113</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.96 [0.313–15.3]</td><td align="left" valign="bottom">ns (p=0.53)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Weight loss, acute COVID-19, n = 84</td><td align="left" valign="bottom">No weight loss, acute COVID-19, n = 34</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.45 [1.83–12.1]</td><td align="left" valign="bottom">p=0.011</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Dyspnea, acute COVID-19, n = 81</td><td align="left" valign="bottom">No dyspnea, acute COVID-19, n = 37</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.45 [0.661–3.27]</td><td align="left" valign="bottom">ns (p=0.43)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Cough, acute COVID-19, n = 83</td><td align="left" valign="bottom">No cough, acute COVID-19, n = 35</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.07 [0.484–2.41]</td><td align="left" valign="bottom">ns (p=0.89)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Fever, acute COVID-19, n = 83</td><td align="left" valign="bottom">No fever, acute COVID-19, n = 35</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.56 [1.12–6.21]</td><td align="left" valign="bottom">ns (p=0.072)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Night sweat, acute COVID-19, n = 74</td><td align="left" valign="bottom">No night sweat, acute COVID-19, n = 44</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.93 [0.902–4.26]</td><td align="left" valign="bottom">ns (p=0.17)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Pain, acute COVID-19, n = 65</td><td align="left" valign="bottom">No pain, acute COVID-19, n = 53</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.339 [0.157–0.713]</td><td align="left" valign="bottom">p=0.021</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">GI symptoms, acute COVID-19, n = 47</td><td align="left" valign="bottom">No GI symptoms, acute COVID-19, n = 71</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.675 [0.316–1.42]</td><td align="left" valign="bottom">ns (p=0.38)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anosmia, acute COVID-19, n = 53</td><td align="left" valign="bottom">No anosmia, acute COVID-19, n = 65</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.09 [0.526–2.28]</td><td align="left" valign="bottom">ns (p=0.85)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Impaired performance, acute COVID-19, n = 106</td><td align="left" valign="bottom">No impaired performance, acute COVID-19, n = 12</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.12 [0.335–3.98]</td><td align="left" valign="bottom">ns (p=0.89)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Sleep disorders, acute COVID-19, n = 40</td><td align="left" valign="bottom">No sleep disorders, acute COVID-19, n = 77</td><td align="char" char="." valign="bottom">117</td><td align="char" char="." valign="bottom">0.887 [0.407–1.91]</td><td align="left" valign="bottom">ns (p=0.82)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anti-infectives, acute COVID-19, n = 64</td><td align="left" valign="bottom">No anti-infectives, acute COVID-19, n = 54</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.56 [1.67–7.9]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Antiplatelet, acute COVID-19, n = 12</td><td align="left" valign="bottom">No antiplatelet, acute COVID-19, n = 106</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.4 [1.23–20.7]</td><td align="left" valign="bottom">ns (p=0.077)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anticoagulatives, acute COVID-19, n = 4</td><td align="left" valign="bottom">No anticoagulatives, acute COVID-19, n = 114</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.98 [0.493–81.8]</td><td align="left" valign="bottom">ns (p=0.32)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Immunosuppression, acute COVID-19, n = 20</td><td align="left" valign="bottom">No immunosuppression, acute COVID-19, n = 98</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">6.89 [2.32–25.5]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anemia, 60-day visit, n = 10</td><td align="left" valign="bottom">No anemia, 60-day visit, n = 108</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">5.82 [1.38–39.8]</td><td align="left" valign="bottom">ns (p=0.072)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Elevated ferritin, 60-day visit, n = 20</td><td align="left" valign="bottom">No elevated ferritin, 60-day visit, n = 98</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.18 [0.825–6.01]</td><td align="left" valign="bottom">ns (p=0.2)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Elevated NTproBNP, 60-day visit, n = 38</td><td align="left" valign="bottom">No elevated NTproBNP, 60-day visit, n = 80</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.29 [1.05–5.1]</td><td align="left" valign="bottom">ns (p=0.084)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Elevated D-dimer, 60-day visit, n = 49</td><td align="left" valign="bottom">No elevated D-dimer, 60-day visit, n = 69</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.9 [1.37–6.28]</td><td align="left" valign="bottom">p=0.023</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Elevated CRP, 60-day visit, n = 18</td><td align="left" valign="bottom">No elevated CRP, 60-day visit, n = 100</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">5.71 [1.89–21.3]</td><td align="left" valign="bottom">p=0.019</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Elevated IL-6, 60-day visit, n = 11</td><td align="left" valign="bottom">No elevated IL-6, 60-day visit, n = 107</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">15.5 [2.81–289]</td><td align="left" valign="bottom">p=0.036</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Iron deficiency, 60-day visit, n = 6</td><td align="left" valign="bottom">No iron deficiency, 60-day visit, n = 112</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.239 [0.0123–1.55]</td><td align="left" valign="bottom">ns (p=0.29)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Age over 65, n = 32</td><td align="left" valign="bottom">No age over 65, n = 86</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.81 [1.23–6.66]</td><td align="left" valign="bottom">p=0.045</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Hospitalized &gt;7 days, acute COVID-19, n = 59</td><td align="left" valign="bottom">No hospitalized &gt;7 days, acute COVID-19, n = 59</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.93 [2.28–11.1]</td><td align="left" valign="bottom">p=0.0026</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Any comorbidity, n = 90</td><td align="left" valign="bottom">No any comorbidity, n = 28</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">6.86 [2.41–24.8]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">&gt;3 comorbidities, n = 37</td><td align="left" valign="bottom">No &gt;3 comorbidities, n = 81</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">6.05 [2.62–14.9]</td><td align="left" valign="bottom">p=0.0026</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Overweight or obesity, n = 72</td><td align="left" valign="bottom">No overweight or obesity, n = 46</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.61 [0.762–3.48]</td><td align="left" valign="bottom">ns (p=0.3)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">&gt;6 symptoms, acute COVID-19, n = 33</td><td align="left" valign="bottom">No &gt;6 symptoms, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.767 [0.333–1.73]</td><td align="left" valign="bottom">ns (p=0.59)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Persistent symptoms, 60-day visit, n = 93</td><td align="left" valign="bottom">No persistent symptoms, 60-day visit, n = 25</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.91 [0.769–5.08]</td><td align="left" valign="bottom">ns (p=0.26)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q1, 60-day visit, n = 31</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q1, 60-day visit, n = 79</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">0.0769 [0.0173–0.24]</td><td align="left" valign="bottom">p=0.0026</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q2, 60-day visit, n = 30</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q2, 60-day visit, n = 80</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">1.12 [0.481–2.62]</td><td align="left" valign="bottom">ns (p=0.83)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q3, 60-day visit, n = 27</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q3, 60-day visit, n = 83</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">1.8 [0.753–4.4]</td><td align="left" valign="bottom">ns (p=0.28)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q4, 60-day visit, n = 22</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q4, 60-day visit, n = 88</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">5.95 [2.13–19.5]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Ambulatory, acute COVID-19, n = 33</td><td align="left" valign="bottom">No ambulatory, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.106 [0.0296–0.299]</td><td align="left" valign="bottom">p=0.0026</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Hospitalized, acute COVID-19, n = 33</td><td align="left" valign="bottom">No hospitalized, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.28 [0.569–2.88]</td><td align="left" valign="bottom">ns (p=0.61)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Oxygen therapy, acute COVID-19, n = 33</td><td align="left" valign="bottom">No oxygen therapy, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.52 [0.676–3.43]</td><td align="left" valign="bottom">ns (p=0.38)</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">ICU, acute COVID-19, n = 19</td><td align="left" valign="bottom">No ICU, acute COVID-19, n = 99</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">6.28 [2.1–23.3]</td><td align="left" valign="bottom">p=0.012</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Male sex, n = 63</td><td align="left" valign="bottom">No male sex, n = 55</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">5.1 [1.75–18.7]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Obesity, n = 22</td><td align="left" valign="bottom">No obesity, n = 96</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.38 [0.0577–1.46]</td><td align="left" valign="bottom">ns (p=0.26)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Current smoker, n = 4</td><td align="left" valign="bottom">No current smoker, n = 114</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.48 [0.0711–12.2]</td><td align="left" valign="bottom">ns (p=0.77)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Ex-smoker, n = 48</td><td align="left" valign="bottom">No ex-smoker, n = 70</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.59 [0.623–4.09]</td><td align="left" valign="bottom">ns (p=0.37)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">CVD, n = 45</td><td align="left" valign="bottom">No CVD, n = 73</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.71 [1.8–13.5]</td><td align="left" valign="bottom">p=0.0042</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Hypertension, n = 34</td><td align="left" valign="bottom">No hypertension, n = 84</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.17 [1.21–8.38]</td><td align="left" valign="bottom">p=0.029</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">PD, n = 24</td><td align="left" valign="bottom">No PD, n = 94</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.17 [0.735–6.02]</td><td align="left" valign="bottom">ns (p=0.18)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">COPD, n = 6</td><td align="left" valign="bottom">No COPD, n = 112</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.3 [0.304–12.7]</td><td align="left" valign="bottom">ns (p=0.39)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Asthma, n = 9</td><td align="left" valign="bottom">No asthma, n = 109</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.37 [0.468–9.85]</td><td align="left" valign="bottom">ns (p=0.29)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Metabolic disorders, n = 50</td><td align="left" valign="bottom">No metabolic disorders, n = 68</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.92 [1.14–7.95]</td><td align="left" valign="bottom">p=0.045</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Hypercholesterolemia, n = 22</td><td align="left" valign="bottom">No hypercholesterolemia, n = 96</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.52 [0.845–7.12]</td><td align="left" valign="bottom">ns (p=0.12)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Diabetes, n = 18</td><td align="left" valign="bottom">No diabetes, n = 100</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.63 [0.816–7.87]</td><td align="left" valign="bottom">ns (p=0.12)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">CKD, n = 6</td><td align="left" valign="bottom">No CKD, n = 112</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.89 [0.851–28.3]</td><td align="left" valign="bottom">ns (p=0.091)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">GITD, n = 17</td><td align="left" valign="bottom">No GITD, n = 101</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.9 [0.892–8.83]</td><td align="left" valign="bottom">ns (p=0.092)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Malignancy, n = 13</td><td align="left" valign="bottom">No malignancy, n = 105</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.333 [0.0178–1.84]</td><td align="left" valign="bottom">ns (p=0.35)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Immune deficiency, n = 5</td><td align="left" valign="bottom">No immune deficiency, n = 113</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">7.42 [1.16–59.3]</td><td align="left" valign="bottom">ns (p=0.052)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Weight loss, acute COVID-19, n = 84</td><td align="left" valign="bottom">No weight loss, acute COVID-19, n = 34</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.02 [0.939–13.5]</td><td align="left" valign="bottom">ns (p=0.13)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Dyspnea, acute COVID-19, n = 81</td><td align="left" valign="bottom">No dyspnea, acute COVID-19, n = 37</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.7 [0.609–5.54]</td><td align="left" valign="bottom">ns (p=0.38)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Cough, acute COVID-19, n = 83</td><td align="left" valign="bottom">No cough, acute COVID-19, n = 35</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.537 [0.206–1.44]</td><td align="left" valign="bottom">ns (p=0.25)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Fever, acute COVID-19, n = 83</td><td align="left" valign="bottom">No fever, acute COVID-19, n = 35</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.15 [0.727–7.9]</td><td align="left" valign="bottom">ns (p=0.24)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Night sweat, acute COVID-19, n = 74</td><td align="left" valign="bottom">No night sweat, acute COVID-19, n = 44</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.33 [0.84–7.55]</td><td align="left" valign="bottom">ns (p=0.17)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Pain, acute COVID-19, n = 65</td><td align="left" valign="bottom">No pain, acute COVID-19, n = 53</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.495 [0.187–1.26]</td><td align="left" valign="bottom">ns (p=0.18)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">GI symptoms, acute COVID-19, n = 47</td><td align="left" valign="bottom">No GI symptoms, acute COVID-19, n = 71</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.503 [0.168–1.34]</td><td align="left" valign="bottom">ns (p=0.23)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anosmia, acute COVID-19, n = 53</td><td align="left" valign="bottom">No anosmia, acute COVID-19, n = 65</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.61 [0.634–4.16]</td><td align="left" valign="bottom">ns (p=0.36)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Impaired performance, acute COVID-19, n = 106</td><td align="left" valign="bottom">No impaired performance, acute COVID-19, n = 12</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.72 [0.486–51]</td><td align="left" valign="bottom">ns (p=0.39)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Sleep disorders, acute COVID-19, n = 40</td><td align="left" valign="bottom">No sleep disorders, acute COVID-19, n = 77</td><td align="char" char="." valign="bottom">117</td><td align="char" char="." valign="bottom">1.13 [0.412–2.91]</td><td align="left" valign="bottom">ns (p=0.84)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anti-infectives, acute COVID-19, n = 64</td><td align="left" valign="bottom">No anti-infectives, acute COVID-19, n = 54</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.89 [1.68–17.9]</td><td align="left" valign="bottom">p=0.012</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Antiplatelet, acute COVID-19, n = 12</td><td align="left" valign="bottom">No antiplatelet, acute COVID-19, n = 106</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.74 [1.01–13.2]</td><td align="left" valign="bottom">ns (p=0.06)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anticoagulatives, acute COVID-19, n = 4</td><td align="left" valign="bottom">No anticoagulatives, acute COVID-19, n = 114</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.7 [0.538–41.1]</td><td align="left" valign="bottom">ns (p=0.17)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Immunosuppression, acute COVID-19, n = 20</td><td align="left" valign="bottom">No immunosuppression, acute COVID-19, n = 98</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">5.35 [1.85–15.6]</td><td align="left" valign="bottom">p=0.0036</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anemia, 60-day visit, n = 10</td><td align="left" valign="bottom">No anemia, 60-day visit, n = 108</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">8.62 [2.23–37.1]</td><td align="left" valign="bottom">p=0.0039</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Elevated ferritin, 60-day visit, n = 20</td><td align="left" valign="bottom">No elevated ferritin, 60-day visit, n = 98</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.2 [0.693–6.42]</td><td align="left" valign="bottom">ns (p=0.2)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Elevated NTproBNP, 60-day visit, n = 38</td><td align="left" valign="bottom">No elevated NTproBNP, 60-day visit, n = 80</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.23 [1.25–8.55]</td><td align="left" valign="bottom">p=0.026</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Elevated D-dimer, 60-day visit, n = 49</td><td align="left" valign="bottom">No elevated D-dimer, 60-day visit, n = 69</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.41 [0.945–6.38]</td><td align="left" valign="bottom">ns (p=0.096)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Elevated CRP, 60-day visit, n = 18</td><td align="left" valign="bottom">No elevated CRP, 60-day visit, n = 100</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.91 [1.63–14.7]</td><td align="left" valign="bottom">p=0.0075</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Elevated IL-6, 60-day visit, n = 11</td><td align="left" valign="bottom">No elevated IL-6, 60-day visit, n = 107</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">32.5 [7.43–230]</td><td align="left" valign="bottom">p=7.5e-05</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Iron deficiency, 60-day visit, n = 6</td><td align="left" valign="bottom">No iron deficiency, 60-day visit, n = 112</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.867 [0.044–5.75]</td><td align="left" valign="bottom">ns (p=0.92)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Age over 65, n = 32</td><td align="left" valign="bottom">No age over 65, n = 86</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">2.8 [1.05–7.4]</td><td align="left" valign="bottom">ns (p=0.055)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Hospitalized &gt;7 days, acute COVID-19, n = 59</td><td align="left" valign="bottom">No hospitalized &gt;7 days, acute COVID-19, n = 59</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">4.37 [1.58–14.2]</td><td align="left" valign="bottom">p=0.012</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Any comorbidity, n = 90</td><td align="left" valign="bottom">No any comorbidity, n = 28</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">8.22 [1.59–151]</td><td align="left" valign="bottom">ns (p=0.065)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">&gt;3 comorbidities, n = 37</td><td align="left" valign="bottom">No &gt;3 comorbidities, n = 81</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">5.55 [2.11–15.5]</td><td align="left" valign="bottom">p=0.0013</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Overweight or obesity, n = 72</td><td align="left" valign="bottom">No overweight or obesity, n = 46</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.72 [0.282–1.87]</td><td align="left" valign="bottom">ns (p=0.53)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">&gt;6 symptoms, acute COVID-19, n = 33</td><td align="left" valign="bottom">No &gt;6 symptoms, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">1.26 [0.438–3.35]</td><td align="left" valign="bottom">ns (p=0.69)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Persistent symptoms, 60-day visit, n = 93</td><td align="left" valign="bottom">No persistent symptoms, 60-day visit, n = 25</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">3.15 [0.831–20.7]</td><td align="left" valign="bottom">ns (p=0.18)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q2, 60-day visit, n = 30</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q2, 60-day visit, n = 80</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">1.87 [0.666–5.07]</td><td align="left" valign="bottom">ns (p=0.26)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q3, 60-day visit, n = 27</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q3, 60-day visit, n = 83</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">0.675 [0.18–2.05]</td><td align="left" valign="bottom">ns (p=0.55)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q4, 60-day visit, n = 22</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q4, 60-day visit, n = 88</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">4.38 [1.53–12.6]</td><td align="left" valign="bottom">p=0.01</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Ambulatory, acute COVID-19, n = 33</td><td align="left" valign="bottom">No ambulatory, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.0952 [0.0052–0.488]</td><td align="left" valign="bottom">p=0.039</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Hospitalized, acute COVID-19, n = 33</td><td align="left" valign="bottom">No hospitalized, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.714 [0.218–2.01]</td><td align="left" valign="bottom">ns (p=0.58)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Oxygen therapy, acute COVID-19, n = 33</td><td align="left" valign="bottom">No oxygen therapy, acute COVID-19, n = 85</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">0.958 [0.316–2.61]</td><td align="left" valign="bottom">ns (p=0.95)</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">ICU, acute COVID-19, n = 19</td><td align="left" valign="bottom">No ICU, acute COVID-19, n = 99</td><td align="char" char="." valign="bottom">118</td><td align="char" char="." valign="bottom">8.06 [2.75–24.5]</td><td align="left" valign="bottom">p=0.00035</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Male sex, n = 82</td><td align="left" valign="bottom">No male sex, n = 63</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.701 [0.361–1.35]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Obesity, n = 28</td><td align="left" valign="bottom">No obesity, n = 117</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.42 [0.169–0.982]</td><td align="left" valign="bottom">ns (p=0.84)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Current smoker, n = 4</td><td align="left" valign="bottom">No current smoker, n = 141</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">3.22 [0.401–66]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Ex-smoker, n = 57</td><td align="left" valign="bottom">No ex-smoker, n = 88</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.27 [0.654–2.49]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">CVD, n = 58</td><td align="left" valign="bottom">No CVD, n = 87</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.851 [0.436–1.66]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Hypertension, n = 44</td><td align="left" valign="bottom">No hypertension, n = 101</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.931 [0.456–1.89]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">PD, n = 27</td><td align="left" valign="bottom">No PD, n = 118</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.38 [0.598–3.26]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">COPD, n = 8</td><td align="left" valign="bottom">No COPD, n = 137</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.04 [0.238–4.58]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Asthma, n = 10</td><td align="left" valign="bottom">No asthma, n = 135</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.05 [0.279–3.92]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Metabolic disorders, n = 63</td><td align="left" valign="bottom">No metabolic disorders, n = 82</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.02 [0.527–1.96]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Hypercholesterolemia, n = 27</td><td align="left" valign="bottom">No hypercholesterolemia, n = 118</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.55 [0.226–1.28]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Diabetes, n = 24</td><td align="left" valign="bottom">No diabetes, n = 121</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.05 [0.434–2.54]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">CKD, n = 10</td><td align="left" valign="bottom">No CKD, n = 135</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.62 [0.442–6.56]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">GITD, n = 20</td><td align="left" valign="bottom">No GITD, n = 125</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.68 [0.649–4.55]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Malignancy, n = 17</td><td align="left" valign="bottom">No malignancy, n = 128</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.7 [0.241–1.94]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Immune deficiency, n = 9</td><td align="left" valign="bottom">No immune deficiency, n = 136</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.824 [0.197–3.24]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Weight loss, acute COVID-19, n = 106</td><td align="left" valign="bottom">No weight loss, acute COVID-19, n = 39</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.34 [0.644–2.84]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Dyspnea, acute COVID-19, n = 98</td><td align="left" valign="bottom">No dyspnea, acute COVID-19, n = 47</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">2.84 [1.39–6.04]</td><td align="left" valign="bottom">ns (p=0.2)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Cough, acute COVID-19, n = 102</td><td align="left" valign="bottom">No cough, acute COVID-19, n = 43</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.97 [0.96–4.17]</td><td align="left" valign="bottom">ns (p=0.88)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Fever, acute COVID-19, n = 106</td><td align="left" valign="bottom">No fever, acute COVID-19, n = 39</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.17 [0.559–2.45]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Night sweat, acute COVID-19, n = 92</td><td align="left" valign="bottom">No night sweat, acute COVID-19, n = 53</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.42 [0.723–2.83]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Pain, acute COVID-19, n = 78</td><td align="left" valign="bottom">No pain, acute COVID-19, n = 67</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.92 [0.993–3.75]</td><td align="left" valign="bottom">ns (p=0.84)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">GI symptoms, acute COVID-19, n = 59</td><td align="left" valign="bottom">No GI symptoms, acute COVID-19, n = 86</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.27 [0.656–2.48]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anosmia, acute COVID-19, n = 62</td><td align="left" valign="bottom">No anosmia, acute COVID-19, n = 83</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.69 [0.874–3.31]</td><td align="left" valign="bottom">ns (p=0.96)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Impaired performance, acute COVID-19, n = 132</td><td align="left" valign="bottom">No impaired performance, acute COVID-19, n = 13</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.13 [0.358–3.69]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Sleep disorders, acute COVID-19, n = 56</td><td align="left" valign="bottom">No sleep disorders, acute COVID-19, n = 88</td><td align="char" char="." valign="bottom">144</td><td align="char" char="." valign="bottom">1.38 [0.708–2.73]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anti-infectives, acute COVID-19, n = 78</td><td align="left" valign="bottom">No anti-infectives, acute COVID-19, n = 67</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.701 [0.362–1.35]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Antiplatelet, acute COVID-19, n = 22</td><td align="left" valign="bottom">No antiplatelet, acute COVID-19, n = 123</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.05 [0.42–2.63]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anticoagulatives, acute COVID-19, n = 9</td><td align="left" valign="bottom">No anticoagulatives, acute COVID-19, n = 136</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">2.18 [0.553–10.7]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Immunosuppression, acute COVID-19, n = 27</td><td align="left" valign="bottom">No immunosuppression, acute COVID-19, n = 118</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.38 [0.598–3.26]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anemia, 60-day visit, n = 16</td><td align="left" valign="bottom">No anemia, 60-day visit, n = 129</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.591 [0.191–1.69]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Elevated ferritin, 60-day visit, n = 26</td><td align="left" valign="bottom">No elevated ferritin, 60-day visit, n = 118</td><td align="char" char="." valign="bottom">144</td><td align="char" char="." valign="bottom">1.29 [0.551–3.07]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Elevated NTproBNP, 60-day visit, n = 52</td><td align="left" valign="bottom">No elevated NTproBNP, 60-day visit, n = 93</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.96 [0.987–3.94]</td><td align="left" valign="bottom">ns (p=0.84)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Elevated D-dimer, 60-day visit, n = 60</td><td align="left" valign="bottom">No elevated D-dimer, 60-day visit, n = 85</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.7 [0.874–3.33]</td><td align="left" valign="bottom">ns (p=0.96)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Elevated CRP, 60-day visit, n = 23</td><td align="left" valign="bottom">No elevated CRP, 60-day visit, n = 122</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.16 [0.475–2.88]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Elevated IL-6, 60-day visit, n = 17</td><td align="left" valign="bottom">No elevated IL-6, 60-day visit, n = 128</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.529 [0.173–1.48]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Iron deficiency, 60-day visit, n = 6</td><td align="left" valign="bottom">No iron deficiency, 60-day visit, n = 138</td><td align="char" char="." valign="bottom">144</td><td align="char" char="." valign="bottom">2.18 [0.412–16.1]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Age over 65, n = 43</td><td align="left" valign="bottom">No age over 65, n = 102</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.69 [0.827–3.51]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Hospitalized &gt;7 days, acute COVID-19, n = 80</td><td align="left" valign="bottom">No hospitalized &gt;7 days, acute COVID-19, n = 65</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.1 [0.569–2.12]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Any comorbidity, n = 112</td><td align="left" valign="bottom">No any comorbidity, n = 33</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.03 [0.47–2.24]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">&gt;3 comorbidities, n = 47</td><td align="left" valign="bottom">No &gt;3 comorbidities, n = 98</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.46 [0.727–2.95]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Overweight or obesity, n = 86</td><td align="left" valign="bottom">No overweight or obesity, n = 59</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.7 [0.358–1.36]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">&gt;6 symptoms, acute COVID-19, n = 42</td><td align="left" valign="bottom">No &gt;6 symptoms, acute COVID-19, n = 103</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.82 [0.885–3.82]</td><td align="left" valign="bottom">ns (p=0.96)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Persistent symptoms, 60-day visit, n = 115</td><td align="left" valign="bottom">No persistent symptoms, 60-day visit, n = 30</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">4.12 [1.71–11.1]</td><td align="left" valign="bottom">ns (p=0.2)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q1, 60-day visit, n = 34</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q1, 60-day visit, n = 100</td><td align="char" char="." valign="bottom">134</td><td align="char" char="." valign="bottom">1.04 [0.476–2.28]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q2, 60-day visit, n = 33</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q2, 60-day visit, n = 101</td><td align="char" char="." valign="bottom">134</td><td align="char" char="." valign="bottom">1.13 [0.512–2.49]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q3, 60-day visit, n = 34</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q3, 60-day visit, n = 100</td><td align="char" char="." valign="bottom">134</td><td align="char" char="." valign="bottom">0.646 [0.289–1.41]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q4, 60-day visit, n = 33</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q4, 60-day visit, n = 101</td><td align="char" char="." valign="bottom">134</td><td align="char" char="." valign="bottom">1.32 [0.603–2.95]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Ambulatory, acute COVID-19, n = 36</td><td align="left" valign="bottom">No ambulatory, acute COVID-19, n = 109</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.911 [0.426–1.94]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Hospitalized, acute COVID-19, n = 37</td><td align="left" valign="bottom">No hospitalized, acute COVID-19, n = 108</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.983 [0.463–2.08]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Oxygen therapy, acute COVID-19, n = 40</td><td align="left" valign="bottom">No oxygen therapy, acute COVID-19, n = 105</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">0.922 [0.442–1.91]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">ICU, acute COVID-19, n = 32</td><td align="left" valign="bottom">No ICU, acute COVID-19, n = 113</td><td align="char" char="." valign="bottom">145</td><td align="char" char="." valign="bottom">1.24 [0.564–2.74]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Male sex, n = 71</td><td align="left" valign="bottom">No male sex, n = 51</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.12 [0.964–4.85]</td><td align="left" valign="bottom">ns (p=0.1)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Obesity, n = 22</td><td align="left" valign="bottom">No obesity, n = 100</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.94 [0.746–5]</td><td align="left" valign="bottom">ns (p=0.22)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Current smoker, n = 3</td><td align="left" valign="bottom">No current smoker, n = 119</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">4.26 [0.397–93.4]</td><td align="left" valign="bottom">ns (p=0.3)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Ex-smoker, n = 45</td><td align="left" valign="bottom">No ex-smoker, n = 77</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.95 [0.897–4.26]</td><td align="left" valign="bottom">ns (p=0.13)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">CVD, n = 49</td><td align="left" valign="bottom">No CVD, n = 73</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.57 [0.727–3.39]</td><td align="left" valign="bottom">ns (p=0.31)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Hypertension, n = 35</td><td align="left" valign="bottom">No hypertension, n = 87</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.56 [0.683–3.54]</td><td align="left" valign="bottom">ns (p=0.34)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">PD, n = 23</td><td align="left" valign="bottom">No PD, n = 99</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.21 [0.869–5.62]</td><td align="left" valign="bottom">ns (p=0.13)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">COPD, n = 7</td><td align="left" valign="bottom">No COPD, n = 115</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.93 [0.615–15.5]</td><td align="left" valign="bottom">ns (p=0.23)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Asthma, n = 9</td><td align="left" valign="bottom">No asthma, n = 113</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.03 [0.208–4.12]</td><td align="left" valign="bottom">ns (p=0.97)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Metabolic disorders, n = 53</td><td align="left" valign="bottom">No metabolic disorders, n = 69</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.73 [0.807–3.73]</td><td align="left" valign="bottom">ns (p=0.22)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Hypercholesterolemia, n = 24</td><td align="left" valign="bottom">No hypercholesterolemia, n = 98</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.03 [0.383–2.61]</td><td align="left" valign="bottom">ns (p=0.96)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Diabetes, n = 21</td><td align="left" valign="bottom">No diabetes, n = 101</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.15 [0.816–5.64]</td><td align="left" valign="bottom">ns (p=0.16)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">CKD, n = 8</td><td align="left" valign="bottom">No CKD, n = 114</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">17.2 [2.9–328]</td><td align="left" valign="bottom">p=0.02</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">GITD, n = 16</td><td align="left" valign="bottom">No GITD, n = 106</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">3.11 [1.07–9.42]</td><td align="left" valign="bottom">ns (p=0.061)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Malignancy, n = 14</td><td align="left" valign="bottom">No malignancy, n = 108</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">4.47 [1.43–15.6]</td><td align="left" valign="bottom">p=0.025</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Immune deficiency, n = 6</td><td align="left" valign="bottom">No immune deficiency, n = 116</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.14 [0.38–12]</td><td align="left" valign="bottom">ns (p=0.43)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Weight loss, acute COVID-19, n = 91</td><td align="left" valign="bottom">No weight loss, acute COVID-19, n = 31</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.56 [0.645–4.08]</td><td align="left" valign="bottom">ns (p=0.41)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Dyspnea, acute COVID-19, n = 82</td><td align="left" valign="bottom">No dyspnea, acute COVID-19, n = 40</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">3.17 [1.31–8.58]</td><td align="left" valign="bottom">p=0.029</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Cough, acute COVID-19, n = 88</td><td align="left" valign="bottom">No cough, acute COVID-19, n = 34</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.856 [0.375–2.01]</td><td align="left" valign="bottom">ns (p=0.76)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Fever, acute COVID-19, n = 92</td><td align="left" valign="bottom">No fever, acute COVID-19, n = 30</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.19 [0.496–3.01]</td><td align="left" valign="bottom">ns (p=0.76)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Night sweat, acute COVID-19, n = 79</td><td align="left" valign="bottom">No night sweat, acute COVID-19, n = 43</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.39 [0.176–0.852]</td><td align="left" valign="bottom">p=0.033</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Pain, acute COVID-19, n = 65</td><td align="left" valign="bottom">No pain, acute COVID-19, n = 57</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.609 [0.282–1.3]</td><td align="left" valign="bottom">ns (p=0.26)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">GI symptoms, acute COVID-19, n = 46</td><td align="left" valign="bottom">No GI symptoms, acute COVID-19, n = 76</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.715 [0.316–1.57]</td><td align="left" valign="bottom">ns (p=0.47)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anosmia, acute COVID-19, n = 51</td><td align="left" valign="bottom">No anosmia, acute COVID-19, n = 71</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.895 [0.41–1.92]</td><td align="left" valign="bottom">ns (p=0.82)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Impaired performance, acute COVID-19, n = 111</td><td align="left" valign="bottom">No impaired performance, acute COVID-19, n = 11</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.84 [0.238–3.38]</td><td align="left" valign="bottom">ns (p=0.82)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Sleep disorders, acute COVID-19, n = 46</td><td align="left" valign="bottom">No sleep disorders, acute COVID-19, n = 75</td><td align="char" char="." valign="bottom">121</td><td align="char" char="." valign="bottom">0.7 [0.309–1.54]</td><td align="left" valign="bottom">ns (p=0.44)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anti-infectives, acute COVID-19, n = 63</td><td align="left" valign="bottom">No anti-infectives, acute COVID-19, n = 59</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.65 [1.22–6]</td><td align="left" valign="bottom">p=0.03</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Antiplatelet, acute COVID-19, n = 17</td><td align="left" valign="bottom">No antiplatelet, acute COVID-19, n = 105</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">4.8 [1.67–15.1]</td><td align="left" valign="bottom">p=0.011</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anticoagulatives, acute COVID-19, n = 7</td><td align="left" valign="bottom">No anticoagulatives, acute COVID-19, n = 115</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.93 [0.615–15.5]</td><td align="left" valign="bottom">ns (p=0.23)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Immunosuppression, acute COVID-19, n = 22</td><td align="left" valign="bottom">No immunosuppression, acute COVID-19, n = 100</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.45 [0.95–6.34]</td><td align="left" valign="bottom">ns (p=0.096)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anemia, 60-day visit, n = 11</td><td align="left" valign="bottom">No anemia, 60-day visit, n = 111</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">4.14 [1.17–16.7]</td><td align="left" valign="bottom">ns (p=0.053)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Elevated ferritin, 60-day visit, n = 21</td><td align="left" valign="bottom">No elevated ferritin, 60-day visit, n = 100</td><td align="char" char="." valign="bottom">121</td><td align="char" char="." valign="bottom">1.37 [0.498–3.6]</td><td align="left" valign="bottom">ns (p=0.58)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Elevated NTproBNP, 60-day visit, n = 44</td><td align="left" valign="bottom">No elevated NTproBNP, 60-day visit, n = 78</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.42 [1.11–5.33]</td><td align="left" valign="bottom">p=0.046</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Elevated D-dimer, 60-day visit, n = 50</td><td align="left" valign="bottom">No elevated D-dimer, 60-day visit, n = 72</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">3.23 [1.49–7.2]</td><td align="left" valign="bottom">p=0.0089</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Elevated CRP, 60-day visit, n = 17</td><td align="left" valign="bottom">No elevated CRP, 60-day visit, n = 105</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">6.6 [2.24–22.3]</td><td align="left" valign="bottom">p=0.0029</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Elevated IL-6, 60-day visit, n = 9</td><td align="left" valign="bottom">No elevated IL-6, 60-day visit, n = 113</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">20.2 [3.52–383]</td><td align="left" valign="bottom">p=0.013</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Iron deficiency, 60-day visit, n = 6</td><td align="left" valign="bottom">No iron deficiency, 60-day visit, n = 115</td><td align="char" char="." valign="bottom">121</td><td align="char" char="." valign="bottom">1.05 [0.142–5.65]</td><td align="left" valign="bottom">ns (p=0.96)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Age over 65, n = 33</td><td align="left" valign="bottom">No age over 65, n = 89</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.55 [1.11–5.88]</td><td align="left" valign="bottom">p=0.046</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Hospitalized &gt;7 days, acute COVID-19, n = 66</td><td align="left" valign="bottom">No hospitalized &gt;7 days, acute COVID-19, n = 56</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">3.83 [1.7–9.21]</td><td align="left" valign="bottom">p=0.0045</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Any comorbidity, n = 93</td><td align="left" valign="bottom">No any comorbidity, n = 29</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">3.95 [1.39–14.2]</td><td align="left" valign="bottom">p=0.032</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">&gt;3 comorbidities, n = 41</td><td align="left" valign="bottom">No &gt;3 comorbidities, n = 81</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.47 [1.12–5.48]</td><td align="left" valign="bottom">p=0.044</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Overweight or obesity, n = 72</td><td align="left" valign="bottom">No overweight or obesity, n = 50</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.24 [0.575–2.73]</td><td align="left" valign="bottom">ns (p=0.64)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">&gt;6 symptoms, acute COVID-19, n = 34</td><td align="left" valign="bottom">No &gt;6 symptoms, acute COVID-19, n = 88</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.538 [0.207–1.29]</td><td align="left" valign="bottom">ns (p=0.23)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Persistent symptoms, 60-day visit, n = 96</td><td align="left" valign="bottom">No persistent symptoms, 60-day visit, n = 26</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.83 [0.702–5.39]</td><td align="left" valign="bottom">ns (p=0.3)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q1, 60-day visit, n = 28</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q1, 60-day visit, n = 84</td><td align="char" char="." valign="bottom">112</td><td align="char" char="." valign="bottom">0.245 [0.0675–0.704]</td><td align="left" valign="bottom">p=0.03</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q2, 60-day visit, n = 27</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q2, 60-day visit, n = 85</td><td align="char" char="." valign="bottom">112</td><td align="char" char="." valign="bottom">2.23 [0.913–5.45]</td><td align="left" valign="bottom">ns (p=0.12)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q3, 60-day visit, n = 28</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q3, 60-day visit, n = 84</td><td align="char" char="." valign="bottom">112</td><td align="char" char="." valign="bottom">0.72 [0.27–1.78]</td><td align="left" valign="bottom">ns (p=0.55)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Anti-S1/S2 IgG Q4, 60-day visit, n = 29</td><td align="left" valign="bottom">No anti-S1/S2 IgG Q4, 60-day visit, n = 83</td><td align="char" char="." valign="bottom">112</td><td align="char" char="." valign="bottom">1.88 [0.784–4.51]</td><td align="left" valign="bottom">ns (p=0.21)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Ambulatory, acute COVID-19, n = 32</td><td align="left" valign="bottom">No ambulatory, acute COVID-19, n = 90</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">0.214 [0.0597–0.603]</td><td align="left" valign="bottom">p=0.017</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Hospitalized, acute COVID-19, n = 32</td><td align="left" valign="bottom">No hospitalized, acute COVID-19, n = 90</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.1 [0.458–2.56]</td><td align="left" valign="bottom">ns (p=0.85)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Oxygen therapy, acute COVID-19, n = 32</td><td align="left" valign="bottom">No oxygen therapy, acute COVID-19, n = 90</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">1.33 [0.561–3.07]</td><td align="left" valign="bottom">ns (p=0.57)</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">ICU, acute COVID-19, n = 26</td><td align="left" valign="bottom">No ICU, acute COVID-19, n = 96</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">2.56 [1.05–6.27]</td><td align="left" valign="bottom">ns (p=0.061)</td></tr></tbody></table><table-wrap-foot><fn><p>CVD = cardiovascular disease; PD = pulmonary disease; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; GITD = gastrointestinal disease; GI = gastrointestinal; CRP = C-reactive protein; ICU = intensive care unit; CT = computed tomography.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table3" position="float"><label>Appendix 1—table 3.</label><caption><title>Feature cluster assignment scheme.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Cluster #</th><th align="left" valign="top">Variable</th></tr></thead><tbody><tr><td align="left" valign="top">1</td><td align="left" valign="top">Male sex, CVD, hypertension, metabolic disorders, anti-infectives, acute COVID-19, elevated NTproBNP, 60-day visit, elevated D-dimer, 60-day visit, hospitalized &gt;7 days, acute COVID-19, &gt;3 comorbidities, overweight</td></tr><tr><td align="left" valign="top">2</td><td align="left" valign="top">Obesity, current smoker, ex-smoker, PD, COPD, asthma, hypercholesterolemia, diabetes, CKD, GITD, malignancy, immune deficiency, GI symptoms, acute COVID-19, anosmia, acute COVID-19, sleep disorders, acute COVID-19, antiplatelet, acute COVID-19, anticoagulatives, acute COVID-19, immunosuppression, acute COVID-19, anemia, 60-day visit, elevated ferritin, 60-day visit, elevated CRP, 60-day visit, elevated IL-6, 60-day visit, iron deficiency, 60-day visit, age over 65, &gt; 6 symptoms, acute COVID-19, anti-S1/S2 IgG Q1, 60-day visit, anti-S1/S2 IgG Q2, 60-day visit, anti-S1/S2 IgG Q3, 60-day visit, anti-S1/S2 IgG Q4, 60-day visit, ambulatory, acute COVID-19, hospitalized, acute COVID-19, oxygen therapy, acute COVID-19, ICU, acute COVID-19, CT severity score 1–5 at 180-day visit, CT severity score &gt;5 at 180-day visit, lung function impairment at 180-day visit</td></tr><tr><td align="left" valign="top">3</td><td align="left" valign="top">Weight loss, acute COVID-19, dyspnea, acute COVID-19, cough, acute COVID-19, fever, acute COVID-19, night sweat, acute COVID-19, pain, acute COVID-19, impaired performance, acute COVID-19, any comorbidity, persistent symptoms, 60-day visit, symptoms at 180-day visit</td></tr></tbody></table><table-wrap-foot><fn><p>CVD = cardiovascular disease; PD = pulmonary disease; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; GITD = gastrointestinal disease; GI = gastrointestinal; CRP = C-reactive protein; ICU = intensive care unit; CT = computed tomography.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table4" position="float"><label>Appendix 1—table 4.</label><caption><title>Development of machine learning models.</title><p>Outcome: outcome variable at the 180-day follow-up visit</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Outcome</th><th align="left" valign="bottom">Classifier type</th><th align="left" valign="bottom">Caret method</th><th align="left" valign="bottom">Description</th><th align="left" valign="bottom">Package</th><th align="left" valign="bottom">Optimal arguments</th></tr></thead><tbody><tr><td align="left" rowspan="6" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" rowspan="5" valign="bottom">model</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C50</td><td align="left" valign="bottom">trials = 10, model = tree, winnow = FALSE</td></tr><tr><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Random Forest</td><td align="left" valign="bottom">randomForest</td><td align="left" valign="bottom">mtry = 27</td></tr><tr><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Support Vector Machines with Radial Basis Function Kernel</td><td align="left" valign="bottom">kernlab</td><td align="left" valign="bottom">sigma = 0.0105, C = 0.5</td></tr><tr><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Neural Network</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">size = 1, decay = 0</td></tr><tr><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.1, lambda = 0.000431</td></tr><tr><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 1, lambda = 0.0523</td></tr><tr><td align="left" rowspan="6" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" rowspan="5" valign="bottom">model</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C50</td><td align="left" valign="bottom">trials = 1, model = rules, winnow = TRUE</td></tr><tr><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Random Forest</td><td align="left" valign="bottom">randomForest</td><td align="left" valign="bottom">mtry = 52</td></tr><tr><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Support Vector Machines with Radial Basis Function Kernel</td><td align="left" valign="bottom">kernlab</td><td align="left" valign="bottom">sigma = 0.00979, C = 0.5</td></tr><tr><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Neural Network</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">size = 1, decay = 0.1</td></tr><tr><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.1, lambda = 0.0419</td></tr><tr><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.1, lambda = 0.00379</td></tr><tr><td align="left" rowspan="6" valign="bottom">Symptoms at 180-day visit</td><td align="left" rowspan="5" valign="bottom">model</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C50</td><td align="left" valign="bottom">trials = 1, model = tree, winnow = FALSE</td></tr><tr><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Random Forest</td><td align="left" valign="bottom">randomForest</td><td align="left" valign="bottom">mtry = 27</td></tr><tr><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Support Vector Machines with Radial Basis Function Kernel</td><td align="left" valign="bottom">kernlab</td><td align="left" valign="bottom">sigma = 0.0109, C = 1</td></tr><tr><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Neural Network</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">size = 3, decay = 0.1</td></tr><tr><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.1, lambda = 0.000247</td></tr><tr><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.1, lambda = 0.0167</td></tr><tr><td align="left" rowspan="6" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" rowspan="5" valign="bottom">model</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">C50</td><td align="left" valign="bottom">trials = 1, model = rules, winnow = FALSE</td></tr><tr><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Random Forest</td><td align="left" valign="bottom">randomForest</td><td align="left" valign="bottom">mtry = 52</td></tr><tr><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Support Vector Machines with Radial Basis Function Kernel</td><td align="left" valign="bottom">kernlab</td><td align="left" valign="bottom">sigma = 0.0108, C = 0.5</td></tr><tr><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Neural Network</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">size = 1, decay = 0.1</td></tr><tr><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.55, lambda = 0.0341</td></tr><tr><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Elastic-Net Regularized Generalized Linear Models</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">alpha = 0.55, lambda = 0.0387</td></tr></tbody></table></table-wrap><table-wrap id="app1table5" position="float"><label>Appendix 1—table 5.</label><caption><title>Performance of machine learning classifiers.</title><p>Outcome: outcome variable at the 180-day follow-up visit; Method: Caret method, Accuracy: model accuracy with 95% confidence intervals, Kappa: model kappa statistic with 95% confidence intervals, AUC: area under the curve.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Outcome</th><th align="left" valign="bottom">Total N</th><th align="left" valign="bottom">Events N</th><th align="left" valign="bottom">Method</th><th align="left" valign="bottom">Data set</th><th align="left" valign="bottom">Accuracy</th><th align="left" valign="bottom">Kappa</th><th align="left" valign="bottom">AUC</th><th align="left" valign="bottom">Sensitivity</th><th align="left" valign="bottom">Specificity</th></tr></thead><tbody><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.72 [0.36–1]</td><td align="char" char="." valign="bottom">0.43 [-0.35–1]</td><td align="char" char="." valign="bottom">0.78</td><td align="char" char="." valign="bottom">0.69</td><td align="char" char="." valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.78 [0.63–0.93]</td><td align="char" char="." valign="bottom">0.55 [0.26–0.85]</td><td align="char" char="." valign="bottom">0.81</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.8</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.98</td><td align="char" char="." valign="bottom">0.86</td><td align="char" char="." valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.71 [0.3–1]</td><td align="char" char="." valign="bottom">0.42 [-0.52–1]</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">0.72</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">cCV</td><td align="char" char="." valign="bottom">0.67 [0.26–1]</td><td align="char" char="." valign="bottom">0.35 [-0.38–1]</td><td align="char" char="." valign="bottom">0.69</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.76</td><td align="char" char="." valign="bottom">0.54</td><td align="char" char="." valign="bottom">0.78</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">0.57</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.73 [0.4–1]</td><td align="char" char="." valign="bottom">0.45 [-0.33–1]</td><td align="char" char="." valign="bottom">0.78</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.75 [0.4–1]</td><td align="char" char="." valign="bottom">0.51 [-0.25–1]</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom">0.78</td><td align="char" char="." valign="bottom">0.73</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.84</td><td align="char" char="." valign="bottom">0.87</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.86 [0.67–1]</td><td align="char" char="." valign="bottom">0.37 [-0.2–1]</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.39</td><td align="char" char="." valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.87</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.43</td><td align="char" char="." valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.88 [0.81–0.96]</td><td align="char" char="." valign="bottom">0.51 [0.044–0.89]</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.45</td><td align="char" char="." valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">0.65</td><td align="char" char="." valign="bottom">0.48</td><td align="char" char="." valign="bottom">0.99</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.84 [0.6–1]</td><td align="char" char="." valign="bottom">0.34 [-0.25–1]</td><td align="char" char="." valign="bottom">0.76</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="." valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.79 [0.5–1]</td><td align="char" char="." valign="bottom">0.31 [-0.29–1]</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.47</td><td align="char" char="." valign="bottom">0.87</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.99</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">0.95</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.84 [0.6–1]</td><td align="char" char="." valign="bottom">0.34 [-0.25–1]</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="." valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.87 [0.63–1]</td><td align="char" char="." valign="bottom">0.43 [-0.23–1]</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.48</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">0.68</td><td align="char" char="." valign="bottom">0.99</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.73 [0.33–1]</td><td align="char" char="." valign="bottom">0.39 [-0.5–1]</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.54</td><td align="char" char="." valign="bottom">0.84</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.86</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.75 [0.61–0.86]</td><td align="char" char="." valign="bottom">0.39 [0.052–0.67]</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.48</td><td align="char" char="." valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.98</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.74 [0.4–1]</td><td align="char" char="." valign="bottom">0.37 [-0.36–1]</td><td align="char" char="." valign="bottom">0.66</td><td align="char" char="." valign="bottom">0.51</td><td align="char" char="." valign="bottom">0.86</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.83</td><td align="char" char="." valign="bottom">0.59</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">0.61</td><td align="char" char="." valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.65 [0.2–1]</td><td align="char" char="." valign="bottom">0.2 [-0.5–1]</td><td align="char" char="." valign="bottom">0.59</td><td align="char" char="." valign="bottom">0.44</td><td align="char" char="." valign="bottom">0.76</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.83</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.73 [0.4–1]</td><td align="char" char="." valign="bottom">0.35 [-0.33–1]</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">0.49</td><td align="char" char="." valign="bottom">0.85</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.72 [0.36–1]</td><td align="char" char="." valign="bottom">0.35 [-0.44–1]</td><td align="char" char="." valign="bottom">0.69</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">0.84</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">38</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.87</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">0.96</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.6 [0.22–0.93]</td><td align="char" char="." valign="bottom">0.2 [-0.51–0.87]</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">0.61</td><td align="char" char="." valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.86</td><td align="char" char="." valign="bottom">0.96</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.58 [0.41–0.74]</td><td align="char" char="." valign="bottom">0.16 [-0.19–0.49]</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">0.52</td><td align="char" char="." valign="bottom">0.63</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.99</td><td align="char" char="." valign="bottom">0.98</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">0.98</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.56 [0.17–0.86]</td><td align="char" char="." valign="bottom">0.13 [-0.64–0.72]</td><td align="char" char="." valign="bottom">0.56</td><td align="char" char="." valign="bottom">0.54</td><td align="char" char="." valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.59 [0.29–0.86]</td><td align="char" char="." valign="bottom">0.17 [-0.52–0.72]</td><td align="char" char="." valign="bottom">0.58</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">0.57</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.56 [0.29–0.86]</td><td align="char" char="." valign="bottom">0.13 [-0.46–0.71]</td><td align="char" char="." valign="bottom">0.59</td><td align="char" char="." valign="bottom">0.56</td><td align="char" char="." valign="bottom">0.56</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="char" char="." valign="bottom">0.54 [0.17–0.83]</td><td align="char" char="." valign="bottom">0.089 [-0.67–0.67]</td><td align="char" char="." valign="bottom">0.55</td><td align="char" char="." valign="bottom">0.45</td><td align="char" char="." valign="bottom">0.62</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="char" char="." valign="bottom">133</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="char" char="." valign="bottom">0.86</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.88</td></tr></tbody></table><table-wrap-foot><fn><p>AUC = area under the curve; CT = computed tomography; glmnet = elastic-net regularized generalized linear models; nnet = neural networks; svmRadial = support vector machines with radial basis function kernel; rf = random forest; ensemble = model ensemble with elastic-net regularized generalized linear models</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table6" position="float"><label>Appendix 1—table 6.</label><caption><title>Performance of machine learning classifiers in the acute COVID-19 severity strata.</title><p>Outcome: outcome variable at the 180-day follow-up visit; cohort subset: cohort acute COVID-19 severity strata (mild–moderate: outpatient or hospitalized without oxygen; severe–critical: oxygen therapy or ICU),</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Outcome</th><th align="left" valign="bottom">Cohort subset</th><th align="left" valign="bottom">Total N</th><th align="left" valign="bottom">Events N</th><th align="left" valign="bottom">Method</th><th align="left" valign="bottom">Data set</th><th align="left" valign="bottom">AUC</th><th align="left" valign="bottom">Sensitivity</th><th align="left" valign="bottom">Specificity</th></tr></thead><tbody><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.93</td><td align="left" valign="bottom">0.84</td><td align="left" valign="bottom">0.87</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.9</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.96</td><td align="left" valign="bottom">0.97</td><td align="left" valign="bottom">0.7</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.57</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.92</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.85</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.86</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">0.43</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.53</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.99</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.73</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.95</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.83</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.97</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.94</td><td align="left" valign="bottom">0.33</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.87</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.65</td><td align="left" valign="bottom">0.48</td><td align="left" valign="bottom">0.99</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.38</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.74</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.96</td><td align="left" valign="bottom">0.89</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.97</td><td align="left" valign="bottom">0.9</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.96</td><td align="left" valign="bottom">0.89</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.94</td><td align="left" valign="bottom">0.85</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.93</td><td align="left" valign="bottom">0.77</td><td align="left" valign="bottom">0.85</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.95</td><td align="left" valign="bottom">0.91</td><td align="left" valign="bottom">0.91</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.92</td><td align="left" valign="bottom">0.82</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.91</td><td align="left" valign="bottom">0.73</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.92</td><td align="left" valign="bottom">0.89</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0.97</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.85</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.81</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.87</td><td align="left" valign="bottom">0.83</td><td align="left" valign="bottom">0.91</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.94</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.96</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.88</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.83</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.82</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">0.64</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.89</td><td align="left" valign="bottom">0.88</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.89</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.84</td><td align="left" valign="bottom">0.29</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.91</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.97</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">Training</td><td align="left" valign="bottom">0.98</td><td align="left" valign="bottom">0.83</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.69</td><td align="left" valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.69</td><td align="left" valign="bottom">0.43</td><td align="left" valign="bottom">0.8</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.85</td><td align="left" valign="bottom">0.62</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.72</td><td align="left" valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.43</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.88</td><td align="left" valign="bottom">0.47</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.8</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.73</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.92</td><td align="left" valign="bottom">0.4</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.69</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.67</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.77</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.62</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.39</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.71</td><td align="left" valign="bottom">0.72</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.66</td><td align="left" valign="bottom">0.78</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.6</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.81</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.8</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.92</td></tr><tr><td align="left" valign="bottom">CT abnormalities at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.87</td><td align="left" valign="bottom">0.55</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">0.39</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.13</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.49</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.73</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">0.95</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.033</td><td align="left" valign="bottom">0.96</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.93</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.48</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.13</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.72</td><td align="left" valign="bottom">0.47</td><td align="left" valign="bottom">0.87</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.84</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.76</td><td align="left" valign="bottom">0.41</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.63</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.51</td><td align="left" valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">109</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.45</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.64</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom">0.98</td></tr><tr><td align="left" valign="bottom">CT severity score &gt;5 at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">51</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.99</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.62</td><td align="left" valign="bottom">0.56</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.6</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.56</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.55</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.52</td><td align="left" valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.45</td><td align="left" valign="bottom">0.62</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.54</td><td align="left" valign="bottom">0.48</td><td align="left" valign="bottom">0.59</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.43</td><td align="left" valign="bottom">0.66</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.57</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.63</td><td align="left" valign="bottom">0.54</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.6</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.54</td><td align="left" valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.6</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.51</td><td align="left" valign="bottom">0.56</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">133</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.52</td><td align="left" valign="bottom">0.63</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">0.63</td></tr><tr><td align="left" valign="bottom">Symptoms at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.49</td><td align="left" valign="bottom">0.63</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">0.54</td><td align="left" valign="bottom">0.84</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.37</td><td align="left" valign="bottom">0.86</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">C5.0</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.63</td><td align="left" valign="bottom">0.81</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.72</td><td align="left" valign="bottom">0.49</td><td align="left" valign="bottom">0.85</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.58</td><td align="left" valign="bottom">0.26</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">rf</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom">0.62</td><td align="left" valign="bottom">0.79</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.69</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">0.84</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.56</td><td align="left" valign="bottom">0.29</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">svmRadial</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.62</td><td align="left" valign="bottom">0.79</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.44</td><td align="left" valign="bottom">0.76</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.47</td><td align="left" valign="bottom">0.29</td><td align="left" valign="bottom">0.83</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">nnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.62</td><td align="left" valign="bottom">0.52</td><td align="left" valign="bottom">0.67</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.66</td><td align="left" valign="bottom">0.51</td><td align="left" valign="bottom">0.86</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.55</td><td align="left" valign="bottom">0.21</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">glmnet</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.73</td><td align="left" valign="bottom">0.68</td><td align="left" valign="bottom">0.83</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Whole cohort</td><td align="left" valign="bottom">111</td><td align="left" valign="bottom">38</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.72</td><td align="left" valign="bottom">0.48</td><td align="left" valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Mild–moderate COVID-19</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.59</td><td align="left" valign="bottom">0.26</td><td align="left" valign="bottom">0.92</td></tr><tr><td align="left" valign="bottom">Lung function impairment at 180-day visit</td><td align="left" valign="bottom">Severe–critical COVID-19</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">24</td><td align="left" valign="bottom">ensemble</td><td align="left" valign="bottom">CV</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">0.61</td><td align="left" valign="bottom">0.85</td></tr></tbody></table><table-wrap-foot><fn><p>AUC = area under the curve; CT = computed tomography; ICU = intensive care unit; glmnet = elastic-net regularized generalized linear models; nnet = neural network; svmRadial = support vector machines with radial basis function kernel; rf = random forest; ensemble = model ensemble with elastic-net regularized generalized linear models</p></fn></table-wrap-foot></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72500.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.06.22.21259316" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.06.22.21259316"/></front-stub><body><p>This is an informative paper describing the incidence and predictors of long-term radiological and functional lung abnormalities following COVID-19. Congratulations on the importance of the work!</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72500.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cheng</surname><given-names>Guang-Shing</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.06.22.21259316">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.06.22.21259316v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Investigating phenotypes of pulmonary COVID- 19 recovery -a longitudinal observational prospective multicenter trial&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Joshua T Schiffer as the Reviewing Editor and Reviewer #2, and the evaluation has been overseen by Jos Van der Meer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Guang-Shing Cheng (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please describe potential methods to operationalize the machine learning approach.</p><p>2) Please take care to precisely define all endpoints throughout the study as per the requests of reviewer 3.</p><p>3) Please provide rationale for using radiologic endpoints rather than clinical and functional endpoints throughout the study and consider further analyses using clinical and functional endpoints.</p><p>4) Please clearly discriminate the radiologic endpoints. If severe abnormalities of a subset of any abnormality, then please explicitly state this. It is necessary to include the number of study participants who meet each endpoint to provide complete clarity.</p><p>5) More precisely describe the meaning of low, medium and high risk in figure 6.</p><p>6) Please be sure that exposure and outcome variables are independent of one another or remove the exposure variable from the analysis.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Well done study, well written, and of great interest to me personally and scientifically.</p><p>1. Would you be able to apply your machine learning algorithms to an external validation cohort from the same time frame? Would lend additional support to your model.</p><p>2. Additional follow-up assessments at 1 year would be informative, but perhaps that data is forthcoming in another manuscript.</p><p>3. How would you operationalize ML algorithms for clinical use?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1) Please justify selection of radiologic endpoints as primary endpoints rather than functional and symptomatic endpoints.</p><p>2) Please define endpoints specifically and explicitly state the number of patients who fall within each endpoint, taking great care to discriminate whether different groups overlap.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72500.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please describe potential methods to operationalize the machine learning approach.</p></disp-quote><p>We appreciate this important point. The applicability of a machine learning algorithm to classify real-life data is the central challenge and the greatest strength of the approach. Unfortunately, our longitudinal one-cohort study does not provide us with a possibility of external validation of the clustering and classification procedures presented in the manuscript. For this reason, we hesitated to discuss extensively the performance features and the reproducibility of the presented machine learning algorithms in the initial manuscript.</p><p>In the revised manuscript we discuss the potential of machine-learning-assisted analysis of medical record data, laboratory and patient self-reported data in early prediction of COVID-19 severity [1–3]⁠ as well as prediction and phenotyping of complicated recovery [3–6]⁠. In addition to gain more confidence in the robustness of the clustering and classification procedures shown in the manuscript, we consistently included the 20-fold cross-validation for all those analyses instead of the repeated holdout strategy used previously (feature cluster validation: Figure 6—figure supplement 1, participant cluster validation: Figure 7—figure supplement 1, validation of machine learning models: Figure 9 and Appendix 1 – table 5).</p><p>Finally, we developed an online, open source pulmonary assessment tools based on the R Shiny platform (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>, code available from <ext-link ext-link-type="uri" xlink:href="https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app">https://github.com/PiotrTymoszuk/COVILD-recovery-assessment-app</ext-link>). The tool implements assignment of the user-provided patient records to the Risk Clusters described in the manuscript. In addition, it enables predictions of any lung CT abnormalities, moderate-to-severe CT abnormalities or functional lung impairment at the 180-day follow-up with the machine learning algorithms presented in the manuscript, which were trained and cross-validated in the CovILD cohort. We believe that such tool can increase the visibility of our work, foster collaboration, and give us an opportunity to validate our clustering approach in the future.</p><disp-quote content-type="editor-comment"><p>2) Please take care to precisely define all endpoints throughout the study as per the requests of reviewer 3.</p></disp-quote><p>We are thankful for pointing out this unclarity. In the revised manuscript, we precisely define the primary (any radiological lung findings at the 6-month follow-up) and secondary endpoints (radiological lung abnormalities with CT score &gt; 5, lung function impairment and persistent symptoms at the 6-month follow-up) of the study and analysis. See: Introduction and Methods/Study design for the description in the text and Table 3 with the numbers and percentages of the study participants reaching the endpoints. The overlap between the subjects reaching the radiological, functional and clinical endpoints is presented in Figure 3—figure supplement 1 and Figure 3—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>3) Please provide rationale for using radiologic endpoints rather than clinical and functional endpoints throughout the study and consider further analyses using clinical and functional endpoints.</p></disp-quote><p>This is an important issue which we clarify in the revised manuscript. First, the study was established after the emergence of the first COVID-19 in Europa in March 2020, and at this time hardly any information was available concerning the pulmonary outcome of COVID-19. One major issue was the concern that comparable to SARS-CoV-1 infection, many patients may develop long-term persistent structural lung abnormalities in general and interstitial lung disease (ILD) in particular following acute COVID-19 pneumonia [7–9]⁠. Thus, we implemented computed tomography as a primary assessment tool, which is the best diagnostic tool to assess early ILD [10,11]⁠.</p><p>Another goal of the CovILD study was to provide evidence for the development of structured follow-up algorithms for COVID-19 patients. As medical resources are limited, especially during a pandemic, we aimed to identify surrogate parameters, which enable us to identify patients at risk for structural pulmonary damage and the need for close-meshed functional and radiological follow-up. In this context, clinical symptoms, which are typically multifactorial and do not necessarily aid early identification of ILD, were used as a secondary outcome parameter.</p><p>Still, we agree, that clinical and functional endpoints are of great interest for the scientific, clinical and patient community. For this reason, we additionally included the long-term symptom persistence and lung function impairment outcome variables in the univariate (Figure 5, Appendix 1 – table 2) and machine learning multi-parameter risk modeling (Figure 9 – 10, Appendix 1 – table 5 and Appendix 1 – table 6). We also compare the frequency of those outcome variables in the Risk Clusters of the study participants (Figure 8).</p><disp-quote content-type="editor-comment"><p>4) Please clearly discriminate the radiologic endpoints. If severe abnormalities of a subset of any abnormality, then please explicitly state this. It is necessary to include the number of study participants who meet each endpoint to provide complete clarity.</p></disp-quote><p>We now clarify this important point in the Introduction, Methods and Results. N numbers of the participants meeting the endpoints at subsequent follow-up visits are presented in Table 2.</p><p>The individuals with CT severity score &gt; 5 were a subset of the participants with any CT abnormality. The same was true for the GGO-positive patients. We agree with Editor and Reviewer 2, that the overlap between the radiological outcomes obscures the message of the clustering and modeling results. To overcome this, we removed the GGO outcome variable from the kinetic (Figure 3) and risk modeling (Figure 4), machine learning classification (Figure 9 and 10) and comparisons of CT abnormality frequency between the patient clusters (Figure 8). Please note that the great majority of the CT findings present in the study collective was anyway classified as GGOs and a detailed characteristic of CT abnormalities will be addressed by another report of our study team (Luger A et al., in revision).</p><p>In the revised manuscript, we differentiate between mild (CT severity score ≤ 5) and moderate-to-severe radiological abnormalities (CT severity score &gt; 5) in feature (Figure 6) and participant clustering (Figure 8). Furthermore, to guarantee the consequent distinction of explanatory and outcome variables, both the feature (Figure 6) and participant clusters (Figure 7) are defined exclusively with non-CT variables. To investigate the association of mild and moderate-to-severe CT abnormalities with other non-CT variables (Figure 6), the CT features are assigned to the no-CT clusters by a k-NN-based label propagation algorithm, i. e. semi-supervised procedure [12,13]⁠ employed in our recent paper as well [6]⁠.</p><disp-quote content-type="editor-comment"><p>5) More precisely describe the meaning of low, medium and high risk in figure 6.</p></disp-quote><p>The nomenclature: low-, intermediate- and high- risk pertains to the frequency of long-term radiological lung abnormalities in the study participant clusters (Figure 8A). We now describe it more clearly in the section ‘Results/Risk stratification for perturbed pulmonary recovery by unsupervised clustering’ before describing other cluster features.</p><disp-quote content-type="editor-comment"><p>6) Please be sure that exposure and outcome variables are independent of one another or remove the exposure variable from the analysis.</p></disp-quote><p>This is an important issue. We agree with the argumentation of the Editor and Reviewer 3 that the inclusion of the overlapping CT responses in risk modeling, clustering and machine learning classification obfuscates the conclusions. For this reason and the reasons described in response to Essential revisions comment 4, we removed the GGO variable from the revised analysis pipeline and differentiate between mild (CT severity score ≤ 5) and moderate-to-severe (CT severity score &gt; 5) radiological lung abnormalities in the modeling, clustering and machine learning classification. In addition, we define symptom and participant clusters solely with the non-CT parameters. See response to Essential revisions comment 4 for details.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Well done study, well written, and of great interest to me personally and scientifically.</p><p>1. Would you be able to apply your machine learning algorithms to an external validation cohort from the same time frame? Would lend additional support to your model.</p></disp-quote><p>This is an extremely important point. As stressed already in the initial version of the manuscript, the optimal performance of clustering and classification algorithms can be achieved with large training cohorts and external validation is a crucial step, which would require an additional cohort with a comparable parameter record. We searched for external collaborators, but unfortunately, none of the contacted collaborating academic pulmonology centers in Europe could provide us with a comparably rich set of demography, clinics, biochemistry, functional and imaging data collected at analogical time points. Furthermore, large cross-sectional observation cohorts, like the Wuhan Study [14]⁠, do not offer open data access.</p><p>In the revised manuscript we tried to improve the robustness of the classifiers and partially address the lacking possibility for external validation:</p><p>1. We do not restrict the analysis to the subset of the CovILD study with the complete set of all variables. Instead, the non-missingness criterion is applied to each outcome variable separately (any CT abnormalities: n = 109, moderate-to-severe abnormalities: n = 109, lung function impairment: n = 111, persistent symptoms: n = 133). This resulted in a greater number of observations used for training of the machine learning algorithms.</p><p>2. We altered the internal validation strategy. Instead of the repeated holdout approach applied to the machine learning classification, which strongly limits the size of the training data set, we switched to 20-fold cross-validation both for the cluster algorithms (as described by Lange et al. [15]⁠, Figure 6—figure supplement 1BD and Figure 7—figure supplement 1BF) and the machine learning models (Figure 9, Appendix 1 – table 5).</p><p>3. The algorithm of clustering of the study participants was changed to a more stable one as investigated by 20-fold cross -validation stability test [15]⁠. Instead of the k-means procedure [16]⁠ applied to the clinical non-CT parameters in the initial manuscript version, a combined self-organizing map (SOM) – hierarchical clustering algorithm is used (Supplementary Figure S6) [17,18]⁠. Importantly, both methods classified the study participants in a comparable way into clusters differing significantly in frequency of pulmonary CT abnormalities (Figure 8). In addition, the cluster assignment was shown to be a significant correlate of persistent radiological lung abnormalities independently of the acute COVID-19 severity (Figure 8—figure supplement 1B), as shown in the initial version of the manuscript.</p><p>4. The set of machine learning models were optimized and includes now multiple tools provided by the R package <italic>caret</italic> [19]⁠<italic>,</italic> which represent various families of machine learning algorithms (rule tree classifier: C5.0 [20]⁠, bagged tree classifier: Random Forests [21]⁠, support vector machines (SVM) with radial kernel [22]⁠, shallow neural networks: nnet [23]⁠ and elastic net: glmnet [24]⁠, Appendix 1 – table 4) and provided more consistent results than the simple kNN and naive Bayes algorithms presented before. Finally, ensemble models being a linear combination of the C5.0, Radom Forests, SVM, nnet and glmnet classifiers were constructed based on the elastic net algorithm and <italic>caretEnsemble</italic> package (Figure 9—figure supplement 2) [25]⁠. Notably, the respective ensemble models showed a superior accuracy at predicting any CT abnormalities and persistent symptoms in the cross-validation setting (Figure 9, Appendix 1 – table 5).</p><p>5. We provide an open-source online R Shiny application (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>) implementing k-NN-based assignment (supervised clustering) [12,13,26]⁠ the user-provided patient’s records to the low-, intermediate- and high-risk clusters (Figure 7) and enables pulmonary outcome prediction by machine learning. We suppose that such tool may foster collaboration and facilitate verification of the manuscript’s findings intramurally and by all interested centers.</p><disp-quote content-type="editor-comment"><p>2. Additional follow-up assessments at 1 year would be informative, but perhaps that data is forthcoming in another manuscript.</p></disp-quote><p>Unfortunately, we are not able to disclose the one-year follow-up data in the revised manuscript, as the radiological and clinical findings of the CovILD cohort are included in a manuscript currently under revision in <italic>Radiology</italic> (Luger A et al.) and we are still working on the analysis of the clinical, cardiopulmonary and mental recovery data for the one-year follow-up time point.</p><disp-quote content-type="editor-comment"><p>3. How would you operationalize ML algorithms for clinical use?</p></disp-quote><p>We appreciate this point. The drawback of the clustering and classification algorithms presented in the manuscript is the large set of input variables (50 non-CT features) precluding manual one-by-one risk computation in clinical routine. As described in response to the public review, an open-source risk cluster classification and machine learning pulmonary outcome prediction tool accompanies now the revised manuscript (<ext-link ext-link-type="uri" xlink:href="https://im2-ibk.shinyapps.io/CovILD/">https://im2-ibk.shinyapps.io/CovILD/</ext-link>). Such tool implements a data sheet (.xlsx) input, enabling concomitant analysis of multiple patient records at a time.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1) Please justify selection of radiologic endpoints as primary endpoints rather than functional and symptomatic endpoints.</p></disp-quote><p>Please see response to the public review for the motivation of the focus on radiological/structural lung recovery.</p><disp-quote content-type="editor-comment"><p>2) Please define endpoints specifically and explicitly state the number of patients who fall within each endpoint, taking great care to discriminate whether different groups overlap.</p></disp-quote><p>Done as requested, please see response to the public review and Table 3 of the revised manuscript.</p><p>References:</p><p>1. Gutmann C, Takov K, Burnap SA, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun 2021;12. doi:10.1038/S41467-021-23494-1</p><p>2. Benito-León J, Castillo MD Del, Estirado A, et al. Using Unsupervised Machine Learning to Identify Age- and Sex-Independent Severity Subgroups Among Patients with COVID-19: Observational Longitudinal Study. J Med Internet Res 2021;23. doi:10.2196/25988</p><p>3. Demichev V, Tober-Lau P, Lemke O, et al. A time-resolved proteomic and prognostic map of COVID-19. Cell Syst 2021;12:780. doi:10.1016/J.CELS.2021.05.005</p><p>4. Estiri H, Strasser ZH, Brat GA, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med 2021;19. doi:10.1186/S12916-021-02115-0</p><p>5. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021;27. doi:10.1038/s41591-021-01292-y</p><p>6. Sahanic S, Tymoszuk P, Ausserhofer D, et al. Phenotyping of acute and persistent COVID-19 features in the outpatient setting: exploratory analysis of an international cross-sectional online survey. Clin Infect Dis Published Online First: 26 November 2021. doi:10.1093/CID/CIAB978</p><p>7. Hui DS, Wong KT, Ko FW, et al. The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest 2005;128:2247–61. doi:10.1378/CHEST.128.4.2247</p><p>8. Ng CK, Chan JWM, Kwan TL, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax 2004;59:889–91. doi:10.1136/THX.2004.023762</p><p>9. Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir. Med. 2020;8:839–42. doi:10.1016/S2213-2600(20)30349-0</p><p>10. Suliman YA, Dobrota R, Huscher D, et al. Pulmonary function tests: High rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256–61. doi:10.1002/ART.39405/ABSTRACT</p><p>11. Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020;8:726. doi:10.1016/S2213-2600(20)30168-5</p><p>12. Leng M, Wang J, Cheng J, et al. Adaptive semi-supervised clustering algorithm with label propagation. J Softw Eng 2014;8:14–22. doi:10.3923/JSE.2014.14.22</p><p>13. Lelis L, Sander J. Semi-supervised density-based clustering. Proc – IEEE Int Conf Data Mining, ICDM 2009;:842–7. doi:10.1109/ICDM.2009.143</p><p>14. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32. doi:10.1016/S0140-6736(20)32656-8</p><p>15. Lange T, Roth V, Braun ML, et al. Stability-Based Validation of Clustering Solutions. Neural Comput 2004;16:1299–323. doi:10.1162/089976604773717621</p><p>16. Hartigan JA, Wong MA. Algorithm AS 136: A K-Means Clustering Algorithm. Appl Stat 1979;28:100. doi:10.2307/2346830</p><p>17. Kohonen T. Self-Organizing Maps. Berlin, Heidelberg: : Springer Berlin Heidelberg 1995. doi:10.1007/978-3-642-97610-0</p><p>18. Vesanto J, Alhoniemi E. Clustering of the self-organizing map. IEEE Trans Neural Networks 2000;11:586–600. doi:10.1109/72.846731</p><p>19. Kuhn M. Building predictive models in R using the caret package. J Stat Softw 2008;28:1–26. doi:10.18637/jss.v028.i05</p><p>20. Quinlan JR. C4.5: Programs for Machine Learning. San Francisco, CA, USA: : Morgan Kaufmann Publishers Inc. 1993. doi:10.5555/152181</p><p>21. Breiman L. Random forests. Mach Learn 2001;45:5–32. doi:10.1023/A:1010933404324</p><p>22. Weston J, Watkins C. Multi-Class Support Vector Machines. 1998.</p><p>23. Ripley BD. Pattern recognition and neural networks. Cambridge University Press 2014. doi:10.1017/CBO9780511812651</p><p>24. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33:1–22. doi:10.18637/jss.v033.i01</p><p>25. Deane-Mayer ZA, Knowles JE. Ensembles of Caret Models [R package caretEnsemble version 2.0.1]. 2019.https://cran.r-project.org/package=caretEnsemble (accessed 13 Dec 2021).</p><p>26. Glennan T, Leckie C, Erfani SM. Improved Classification of Known and Unknown Network Traffic Flows Using Semi-supervised Machine Learning. Lect Notes Comput Sci (including Subser Lect Notes Artif Intell Lect Notes Bioinformatics) 2016;9723:493–501. doi:10.1007/978-3-319-40367-0_33</p><p>27. Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial. Eur Respir J Published Online First: 10 December 2020. doi:10.1183/13993003.03481-2020</p></body></sub-article></article>